Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season

Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccines

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03688620

Enrollment

1060

Registered

2018-09-28

Start date

2018-10-05

Completion date

2019-01-04

Last updated

2024-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza, Human

Keywords

Pilot study, Safety surveillance, Quadrivalent seasonal influenza vaccine, Influenza

Brief summary

The purpose of this study is to comply with the European Medicines Agency (EMA) guidance on enhanced safety surveillance for seasonal influenza vaccines in the European Union (EU) and aims to assess adverse events of interest (AEIs) experienced within 7 days post vaccination with GSK's quadrivalent seasonal influenza vaccine (AlphaRix Tetra in Belgium; Influsplit Tetra in Germany, Fluarix Tetra in Spain). This study may help to inform decisions regarding future influenza vaccine safety surveillance for influenza vaccines in Europe.

Detailed description

The key objective of the EMA enhanced safety surveillance is to rapidly detect a significant increase in the frequency and/or severity of expected reactions (local, systemic or allergic reactions) that may indicate a potential risk. The study is a passive enhanced safety surveillance aiming to collect prospectively AEIs and/or other AEs experienced within 7 days post vaccination with GSK's quadrivalent seasonal influenza vaccine, using customized Adverse Drug Reaction cards. Data will be collected via the healthcare provide (HCP) or study medical staff who administer the seasonal influenza vaccination or who provide the inform consent form and the ADR cards.

Interventions

OTHERPassive enhanced safety surveillance

Prospective data collection starting at Visit 1 (Day 1) and ending at Visit 2 (Day 8 or when the ADR card was returned by mail) for all subjects who have previously been vaccinated against influenza in preceding seasons or aged ≥9 years at the time of vaccination, or ending at Visit 4 (Day 36 or when the last ADR card was returned by mail) for children aged \<9 years who have not previously been vaccinated against influenza in preceding seasons). Subjects had up to 14 days post vaccination to return their ADR card (at the next study visit or by mail).

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Months to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., complete the ADR card, return for the next scheduled visit or return the ADR card by mail within a timely manner). * A male or female subject vaccinated with GSK's quadrivalent seasonal influenza vaccine (one or two dose schedule) according to the routine medical practices between 01 October 2018 and 31 December 2018. * Subjects aged 6 months or above at the time of the vaccination according to the countries' specificities. * Written informed consent/informed assent obtained from the subjects/subjects' parent(s)/Legally Acceptable Representative(s) (LARs).

Exclusion criteria

• Child in care.

Design outcomes

Primary

Measure	Time frame	Description
Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for eye disorders.
Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. There were no predefined AEIs listed on the ADR card for eye disorders.
Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for injury, poisoning and procedural complications.
Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. There were no predefined AEIs listed on the ADR card for injury, poisoning and procedural complications.
Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for investigations.
Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52.There were no predefined AEIs listed on the ADR card for investigations.
Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for vascular disorders.
Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. There were no predefined AEIs listed on the ADR card for vascular disorders.
Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between Intenational Organization for Standardization (ISO) weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards.
Cumulative Percentage of Subjects Reporting Any AEIs and/or AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52.
Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were diarrhoea, nausea, and vomiting.
Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were diarrhoea, nausea, and vomiting.
Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were chills, face oedema, fatigue, injection site erythema, injection site pain, injection site swelling, and pyrexia.
Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were chills, face oedema, fatigue, injection site erythema, injection site pain, injection site swelling, and pyrexia.
Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were anaphylactic reaction and hypersensitivity.
Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were anaphylactic reaction and hypersensitivity.
Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were conjunctivitis and rhinitis.
Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were conjunctivitis and rhinitis.
Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEI listed on the ADR card was decreased appetite.
Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEI listed on the ADR card was decreased appetite.
Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were arthropathy and myalgia.
Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were arthropathy and myalgia.
Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were febrile convulsion and headache.
Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were febrile convulsion and headache.
Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEI listed on the ADR card was irritability.
Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEI listed on the ADR card was irritability.
Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were cough, dysphonia, epistaxis, nasal congestion, oropharyngeal pain, rhinorrhoea, and wheezing.
Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were cough, dysphonia, epistaxis, nasal congestion, oropharyngeal pain, rhinorrhoea, and wheezing.
Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were rash and rash generalised.
Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were rash and rash generalised.
Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for cardiac disorders.
Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. There were no predefined AEIs listed on the ADR card for cardiac disorders.
Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for ear and labyrinth disorders.
Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. There were no predefined AEIs listed on the ADR card for ear and labyrinth disorders.

Secondary

Measure	Time frame	Description
Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°36 for the overall (across age strata) post-dose 2 results.
Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°38 for the overall (across age strata) post-dose 2 results.
Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°40 for the overall (across age strata) post-dose 2 results.
Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°42 for the overall (across age strata) post-dose 2 results.
Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°44 for the overall (across age strata) post-dose 2 results.
Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°46 for the overall (across age strata) post-dose 2 results.
Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°48 for the overall (across age strata) post-dose 2 results.
Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°50 for the overall (across age strata) post-dose 2 results.
Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°52 for the overall (across age strata) post-dose 2 results.
Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°54 for the overall (across age strata) post-dose 2 results.
Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°56 for the overall (across age strata) post-dose 2 results.
Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°58 for the overall (across age strata) post-dose 2 results.
Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°60 for the overall (across age strata) post-dose 2 results.
Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°62 for the overall (across age strata) post-dose 2 results.
Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°64 for the overall (across age strata) post-dose 2 results.
Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°66 for the overall (across age strata) post-dose 2 results.
Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°68 for the overall (across age strata) post-dose 2 results.
Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°2 for the overall (across age strata) post-dose 2 results.
Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°4 for the overall (across age strata) post-dose 2 results.
Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°6 for the overall (across age strata) post-dose 2 results.
Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°8 for the overall (across age strata) post-dose 2 results.
Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°10 for the overall (across age strata) post-dose 2 results.
Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°12 for the overall (across age strata) post-dose 2 results.
Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°14 for the overall (across age strata) post-dose 2 results.
Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°16 for the overall (across age strata) post-dose 2 results.
Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°18 for the overall (across age strata) post-dose 2 results.
Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°20 for the overall (across age strata) post-dose 2 results.
Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°22 for the overall (across age strata) post-dose 2 results.
Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°24 for the overall (across age strata) post-dose 2 results.
Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°26 for the overall (across age strata) post-dose 2 results.
Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°28 for the overall (across age strata) post-dose 2 results.
Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°30 for the overall (across age strata) post-dose 2 results.
Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°32 for the overall (across age strata) post-dose 2 results.
Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°34 for the overall (across age strata) post-dose 2 results.
Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were diarrhoea, nausea, and vomiting. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were diarrhoea, nausea, and vomiting. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were diarrhoea, nausea, and vomiting. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for cardiac disorders.
Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e. week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.
Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. There were no predefined AEIs listed on the ADR card for cardiac disorders.
Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for ear and labyrinth disorders.
Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. There were no predefined AEIs listed on the ADR card for ear and labyrinth disorders.
Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for eye disorders.
Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. There were no predefined AEIs listed on the ADR card for eye disorders.
Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for injury, poisoning and procedural complications.
Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. There were no predefined AEIs listed on the ADR card for injury, poisoning and procedural complications.
Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for investigations.
Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. There were no predefined AEIs listed on the ADR card for investigations.
Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were chills, face oedema, fatigue, injection site erythema, injection site pain, injection site swelling, and pyrexia.
Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were chills, face oedema, fatigue, injection site erythema, injection site pain, injection site swelling, and pyrexia.
Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were anaphylactic reaction and hypersensitivity.
Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52.
Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were conjunctivitis and rhinitis.
Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were conjunctivitis and rhinitis.
Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card was decreased appetite.
Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card was decreased appetite.
Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were arthropathy and myalgia.
Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were arthropathy and myalgia.
Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were febrile convulsion and headache.
Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were febrile convulsion and headache.
Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEI listed on the ADR card was irritability.
Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEI listed on the ADR card was irritability.
Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for vascular disorders.
Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. There were no predefined AEIs listed on the ADR card for vascular disorders.
Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were cough, dysphonia, epistaxis, nasal congestion, oropharyngeal pain, rhinorrhoea, and wheezing.
Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were cough, dysphonia, epistaxis, nasal congestion, oropharyngeal pain, rhinorrhoea, and wheezing.
Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were rash and rash generalised.
Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were rash and rash generalised.
Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards.
Weekly Percentage of Subjects Reporting Any AEIs and/or AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52.
Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were diarrhoea, nausea, and vomiting.
Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days	The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were diarrhoea, nausea, and vomiting.

Countries

Belgium, Germany, Spain

Participant flow

Recruitment details

GSK's quadrivalent seasonal influenza vaccine (AlphaRix Tetra in Belgium; Influsplit Tetra in Germany, Fluarix Tetra in Spain) was administered to subjects in this study

Pre-assignment details

Subjects aged \<9 years in Vaccinated\_Fluarix Tetra Group (Spain) who were not vaccinated against influenza in preceding seasons received 2 doses of quadrivalent seasonal influenza vaccine in this study. Subjects from other groups received only 1 dose of the vaccine. Dose 2 results correspond to only some subjects in Vaccinated\_Fluarix Tetra Group.

Participants by arm

Arm	Count
Vaccinated_AlphaRix Tetra Group Volunteered male and female subjects, 18 years of age and above, who received in Belgium one dose of GlaxoSmithKline's (GSK's) quadrivalent seasonal influenza vaccine (AlphaRix Tetra) between 01 October and 31 December 2018.	329
Vaccinated_Influsplit Tetra Group Volunteered subjects male and female subjects, 18 years of age and above, who received in Germany one dose of GSK's quadrivalent seasonal influenza vaccine (Influsplit Tetra) between 01 October and 31 December 2018.	278
Vaccinated_Fluarix Tetra Group Volunteered male and female subjects, between 6 months and 65 years of age, who received in Spain one or two dose(s) of GSK's quadrivalent seasonal influenza vaccine (Fluarix Tetra) between 01 October and 31 December 2018.	453
Total	1,060

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002
Overall Study	Lost to Follow-up	16	0	1
Overall Study	Other	0	0	1
Overall Study	Unwilling to attend the scheduled visit	0	1	0
Overall Study	Withdrawal by Subject	0	0	6

Baseline characteristics

Characteristic	Vaccinated_AlphaRix Tetra Group	Vaccinated_Influsplit Tetra Group	Vaccinated_Fluarix Tetra Group	Total
Age, Continuous	61.3 Years STANDARD_DEVIATION 18.2	65.0 Years STANDARD_DEVIATION 15.1	15.7 Years STANDARD_DEVIATION 18.7	42.8 Years STANDARD_DEVIATION 29.4
Race/Ethnicity, Customized Asian - central / south asian heritage	1 Participants	1 Participants	1 Participants	3 Participants
Race/Ethnicity, Customized Asian - east asian heritage	4 Participants	1 Participants	0 Participants	5 Participants
Race/Ethnicity, Customized Asian - south east asian heritage	2 Participants	0 Participants	0 Participants	2 Participants
Race/Ethnicity, Customized Black or african american	0 Participants	2 Participants	1 Participants	3 Participants
Race/Ethnicity, Customized Other, Not specified	0 Participants	0 Participants	4 Participants	4 Participants
Race/Ethnicity, Customized White - arabic / north african heritage	1 Participants	0 Participants	3 Participants	4 Participants
Race/Ethnicity, Customized White - caucasian / european heritage	321 Participants	274 Participants	444 Participants	1039 Participants
Sex: Female, Male Female	147 Participants	166 Participants	231 Participants	544 Participants
Sex: Female, Male Male	182 Participants	112 Participants	222 Participants	516 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk
deaths Total, all-cause mortality	0 / 329	0 / 278	0 / 453
other Total, other adverse events	139 / 329	102 / 278	227 / 453
serious Total, serious adverse events	0 / 329	0 / 278	0 / 453

Outcome results

Primary

Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between Intenational Organization for Standardization (ISO) weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-47	42.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-49	42.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-48	42.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-43	45.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-51	42.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-44	47.12 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-52	42.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-45	43.97 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-42	45.39 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-50	42.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-46	42.53 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-45	36.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-46	36.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-44	33.62 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-47	36.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-52	36.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-42	34.31 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-50	36.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-48	36.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-40	32.86 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-51	36.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-49	36.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-43	34.56 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-41	34.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-48	47.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-42	44.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-43	46.15 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-44	42.56 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-45	46.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-46	45.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-47	46.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-49	47.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-50	47.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-51	47.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-52	47.46 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-49	43.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-45	42.63 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-44	40.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-40	32.86 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-50	43.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-43	41.04 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-42	39.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-52	43.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-51	43.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-48	43.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-47	42.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-46	41.96 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall	Week 40-41	34.78 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Any AEIs and/or AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 2 vaccination (i.e., week 46 for the second dose) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 46 and 52.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with a second dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card. This analysis was performed only for the Fluarix Tetra Group, and not on the other groups who did not received this second dose.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEIs and/or AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any, Weeks 40-46	33.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEIs and/or AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any, Weeks 40-47	45.45 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEIs and/or AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any, Weeks 40-48	44.68 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEIs and/or AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any, Weeks 40-49	30.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEIs and/or AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any, Weeks 40-50	23.58 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEIs and/or AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any, Weeks 40-51	23.70 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEIs and/or AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any, Weeks 40-52	23.74 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for cardiac disorders.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	1.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-40	1.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-41	0.62 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	0.62 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-40	1.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-41	0.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	1.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	0.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.09 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	0 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for ear and labyrinth disorders.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-44	0.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-46	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-47	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-48	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	1.24 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.98 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.92 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.86 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	1.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	1.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-51	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-41	0.62 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-41	0.62 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-50	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-52	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-49	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-45	0.80 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-44	0.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-45	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-46	0.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-49	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.50 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	1.24 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-50	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-48	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-47	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-46	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-45	0.23 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-49	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-52	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-50	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-46	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-41	0.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-47	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-48	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-41	0.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.66 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-51	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.66 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-52	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.66 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.66 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Weeks 40-49	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.66 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.67 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.68 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.63 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.39 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Weeks 40-51	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Weeks 40-47	0.10 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	0 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for eye disorders.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-44	0.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	1.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	1.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	0.62 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	1.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	1.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	1.09 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	1.47 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-40	1.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-41	0.62 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	0.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-41	0.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-40	1.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.45 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.63 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	1.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.58 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.76 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.38 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-47	9.09 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-48	4.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-49	2.47 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-50	1.63 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-51	1.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-52	1.44 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Eye pruritus,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Eye pruritus,Weeks 40-47	9.09 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Eye pruritus,Weeks 40-50	1.63 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Eye pruritus,Weeks 40-51	1.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Eye pruritus,Weeks 40-52	1.44 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were diarrhoea, nausea, and vomiting.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-45	1.77 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-44	1.44 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-46	1.62 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-47	1.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-43	2.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-48	1.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	5.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-44	3.37 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-49	1.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-51	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-45	1.77 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-50	1.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	6.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-51	1.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-45	3.90 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	6.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-52	1.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	6.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-46	3.90 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-46	1.95 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-47	4.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-48	4.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	3.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-47	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-49	4.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	6.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	6.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-50	4.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	6.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-51	4.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-48	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	6.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-52	4.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-52	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-43	1.16 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-49	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-42	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-43	1.16 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	6.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-44	1.44 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-50	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	5.04 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-49	3.24 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	5.04 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	2.48 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-50	3.24 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	2.86 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-51	3.24 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-52	3.24 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	5.04 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-41	0.62 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-42	1.47 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	5.04 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-43	1.84 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	5.07 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-44	1.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-40	2.86 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-45	1.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-41	2.48 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-46	1.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	5.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-47	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-48	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-42	3.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-49	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-50	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-51	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-52	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-43	3.23 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	4.74 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-44	3.45 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	5.04 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-45	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	4.61 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-46	3.26 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	5.04 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-47	3.24 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	4.41 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-48	3.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	6.84 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	6.84 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	6.84 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	6.84 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-42	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-43	4.62 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-44	4.10 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-45	3.71 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-46	4.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-47	3.89 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-48	3.97 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-49	3.97 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-50	3.97 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-51	3.97 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-52	3.97 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-42	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-43	3.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-44	3.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-50	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-45	2.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-46	2.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-47	2.97 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-48	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-49	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-51	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-52	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-42	5.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-43	4.62 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-44	4.10 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-45	3.14 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-46	2.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-47	2.97 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-48	3.09 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-49	3.09 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-50	3.09 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-51	3.09 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-52	3.09 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-46	0.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-43	2.31 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-44	1.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-45	0.86 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-46	0.72 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-47	0.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-48	0.66 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-49	0.66 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-50	0.66 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-51	0.66 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-52	0.66 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	6.84 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	8.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	7.18 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	5.71 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	6.47 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	6.64 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-48	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-47	0.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	2.86 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-46	0.30 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-45	0.34 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-44	0.47 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-43	0.58 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-49	3.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	2.48 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-48	3.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-47	3.07 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	6.32 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	4.03 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-46	3.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-45	3.06 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	6.32 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-52	1.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-51	1.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	5.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-50	1.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-49	1.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-44	2.99 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-48	1.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-47	1.72 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-46	1.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-45	1.81 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-43	2.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-44	1.73 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-43	1.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	6.32 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-42	1.01 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	5.67 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-52	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-42	2.27 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-51	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-50	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-41	2.48 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-49	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-48	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	6.23 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-47	3.07 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-46	2.90 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	5.78 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-45	2.61 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-44	2.68 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-40	2.86 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-43	2.31 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-42	2.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	6.32 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-41	0.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	6.32 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-52	3.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-51	3.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	6.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-52	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-51	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-50	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Weeks 40-49	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Weeks 40-50	3.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Weeks 40-51	0.09 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-46	33.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-47	13.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-48	6.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-49	3.70 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-50	3.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-51	2.96 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-52	2.88 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Diarrhoea,Weeks 40-46	33.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Diarrhoea,Weeks 40-47	4.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Diarrhoea,Weeks 40-48	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Diarrhoea,Weeks 40-49	1.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Diarrhoea,Weeks 40-50	1.63 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Diarrhoea,Weeks 40-51	1.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Diarrhoea,Weeks 40-52	1.44 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nausea,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nausea,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nausea,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nausea,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nausea,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nausea,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nausea,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Vomiting,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Vomiting,Weeks 40-47	4.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Vomiting,Weeks 40-48	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Vomiting,Weeks 40-49	1.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Vomiting,Weeks 40-50	0.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Vomiting,Weeks 40-51	0.74 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Vomiting,Weeks 40-52	0.72 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Abdominal pain,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Abdominal pain,Weeks 40-47	4.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Abdominal pain,Weeks 40-48	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Abdominal pain,Weeks 40-49	1.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Abdominal pain,Weeks 40-50	0.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Abdominal pain,Weeks 40-51	0.74 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Abdominal pain,Weeks 40-52	0.72 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were chills, face oedema, fatigue, injection site erythema, injection site pain, injection site swelling, and pyrexia.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-42	4.96 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-43	6.40 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-44	5.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-45	4.61 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-46	4.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-47	5.17 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-48	5.17 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-49	5.17 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-50	5.17 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-51	5.17 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-52	5.17 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-44	0.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-46	0.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-47	0.61 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-48	0.61 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-49	0.61 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-50	0.61 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-51	0.61 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-52	0.61 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-44	0.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-44	0.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	31.21 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	29.07 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	31.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	27.66 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	26.62 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	26.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	26.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	26.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	26.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	26.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	26.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-43	0.58 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-44	1.44 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-45	1.42 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-46	1.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-47	1.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-48	1.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-49	1.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-50	1.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-51	1.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-52	1.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-44	0.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-42	2.84 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-43	2.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-44	4.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-45	4.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-46	3.90 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-47	3.95 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-48	3.95 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-49	3.95 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-50	3.95 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-51	3.95 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-52	3.95 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-43	1.16 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-44	1.44 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-45	1.77 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-46	2.27 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-47	3.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-48	3.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-49	3.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-50	3.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-51	3.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-52	3.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-42	28.37 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-43	26.16 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-44	25.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-45	21.63 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-46	20.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-47	19.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-48	19.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-49	19.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-50	19.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-51	19.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-52	19.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-42	2.45 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-52	7.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-50	7.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-43	2.30 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-51	16.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-44	2.16 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-40	17.14 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-51	7.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-45	2.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-47	16.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-46	2.54 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-41	18.01 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-52	7.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-47	2.52 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-48	2.52 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-40	8.57 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-49	2.52 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-41	8.07 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-50	2.52 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-41	0.62 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-42	16.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-51	2.52 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-40	11.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-41	10.56 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-42	8.82 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-42	10.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-43	9.68 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-52	2.52 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-44	9.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-45	10.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-50	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-46	10.87 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-43	8.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-47	10.79 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-48	10.79 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-49	10.79 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-50	16.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-50	10.79 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-44	8.19 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-43	16.13 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-51	10.79 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-52	10.79 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-41	0.62 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-40	2.86 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-41	1.24 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-42	0.98 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-49	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-43	0.92 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-45	7.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-44	0.86 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-45	0.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-46	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-48	16.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-47	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-46	7.61 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-48	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-48	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-49	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-50	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-44	15.95 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-51	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-51	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-47	7.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-52	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-47	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-52	16.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-48	7.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-40	5.71 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-45	17.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-41	6.21 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-46	1.09 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-42	6.86 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-49	16.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-49	7.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-45	1.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-43	7.37 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	25.71 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	27.95 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-44	7.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	27.45 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	26.73 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-50	7.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-45	8.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	26.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	28.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-46	7.97 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	27.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-41	0.62 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	27.70 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-46	16.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	27.70 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-47	7.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-51	7.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	27.70 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-52	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	27.70 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-48	7.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	27.70 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	27.70 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-49	7.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-41	1.86 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-44	0.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-45	0.57 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-46	0.48 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-47	0.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-48	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-49	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-50	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-51	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-52	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-46	0.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	26.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	26.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	24.10 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	28.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	28.06 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	29.06 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	30.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	30.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	30.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	30.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	30.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-43	3.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-44	2.56 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-45	2.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-46	2.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-47	2.97 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-48	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-49	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-50	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-51	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-52	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-43	0.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-44	0.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-45	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-46	0.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-42	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-43	6.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-44	7.18 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-45	6.86 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-46	7.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-47	7.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-48	7.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-49	7.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-50	7.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-51	7.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-52	7.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-42	5.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-43	6.15 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-44	6.15 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-45	5.71 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-46	5.76 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-47	5.49 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-48	5.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-49	5.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-50	5.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-51	5.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-52	5.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-42	15.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-43	10.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-44	8.72 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-45	13.71 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-46	14.39 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-47	15.10 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-48	16.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-49	16.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-50	16.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-51	16.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-52	16.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-42	5.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-43	6.15 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-44	5.13 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-45	5.71 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-46	6.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-47	6.86 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-48	7.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-49	7.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-50	7.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-51	7.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-52	7.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-42	5.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-43	10.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-44	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-45	6.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-46	6.47 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-47	6.41 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-48	6.40 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-49	6.40 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-50	6.40 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-51	6.40 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-52	6.40 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-45	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-46	0.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-46	0.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-45	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-46	0.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-51	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-52	17.64 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-51	17.64 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-48	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-50	17.64 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-49	17.64 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-47	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-48	17.64 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-47	16.95 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-46	16.78 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-45	17.23 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-51	0.47 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-44	16.85 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-43	17.92 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-46	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-42	20.65 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-41	18.01 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-45	0.23 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Weeks 40-40	17.14 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-52	5.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-51	5.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-50	5.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-52	0.47 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-49	5.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-48	5.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-47	5.27 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-46	5.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-45	4.99 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-44	5.35 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-43	5.39 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-42	5.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-41	8.07 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Weeks 40-40	8.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-52	6.51 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-51	6.51 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-50	6.51 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-49	6.51 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-48	6.51 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-47	6.61 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-46	6.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-45	6.46 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-46	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-44	6.46 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-43	5.78 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-47	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-42	5.04 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-41	6.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-48	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Weeks 40-40	5.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-52	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-52	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-49	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-51	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-50	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-50	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-49	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-48	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-51	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-47	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-46	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Weeks 40-52	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-45	0.23 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-44	0.31 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-41	0.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-49	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-52	2.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-51	2.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-50	2.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-49	2.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-48	2.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-47	2.39 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-46	2.30 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-45	2.04 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-44	2.05 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-43	1.93 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-42	1.76 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-41	1.86 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	28.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-51	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	28.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	28.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	28.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	28.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	27.97 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	27.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-41	0.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	27.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	27.24 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	27.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	28.72 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-50	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	27.95 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	25.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-44	0.31 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-47	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-46	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-45	0.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-46	0.50 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-48	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-47	0.48 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-52	3.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-51	3.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-50	3.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-49	3.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-48	3.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-47	3.07 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-46	3.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-45	2.83 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-48	0.47 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-44	2.83 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-43	2.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-52	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-42	1.26 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-41	1.24 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-51	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Weeks 40-40	2.86 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-52	7.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-41	0.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-51	7.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-50	7.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-49	0.47 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-49	7.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-48	7.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-50	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-47	7.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-46	6.99 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Weeks 40-49	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-45	6.69 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-44	6.93 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-43	7.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-42	7.81 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Weeks 40-50	0.47 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-41	10.56 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Weeks 40-40	11.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Weeks 40-41	0.00 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-50	8.94 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-51	8.89 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-47	31.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-48	17.02 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-49	11.11 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-52	9.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Chills,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Chills,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Chills,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Chills,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Chills,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Chills,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Chills,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Face oedema,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Face oedema,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Face oedema,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Face oedema,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Face oedema,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Face oedema,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Face oedema,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Fatigue,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Fatigue,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Fatigue,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Fatigue,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Fatigue,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Fatigue,Weeks 40-51	0.74 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Fatigue,Weeks 40-52	0.72 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site erythema,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site erythema,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site erythema,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site erythema,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site erythema,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site erythema,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site erythema,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site pain,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site pain,Weeks 40-47	27.27 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site pain,Weeks 40-48	14.89 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site pain,Weeks 40-49	8.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site pain,Weeks 40-50	5.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site pain,Weeks 40-51	5.19 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site pain,Weeks 40-52	5.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site swelling,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site swelling,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site swelling,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site swelling,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site swelling,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site swelling,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site swelling,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Pyrexia,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Pyrexia,Weeks 40-47	9.09 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Pyrexia,Weeks 40-48	6.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Pyrexia,Weeks 40-49	4.94 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Pyrexia,Weeks 40-50	4.88 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Pyrexia,Weeks 40-51	4.44 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Pyrexia,Weeks 40-52	5.04 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were anaphylactic reaction and hypersensitivity.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-51	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-49	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-48	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-47	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hypersensitivity,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Anaphylactic reaction,Weeks 40-46	0.00 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	0 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were conjunctivitis and rhinitis.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-49	3.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-43	1.74 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-50	3.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-50	4.56 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-46	4.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-51	3.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-45	3.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-52	3.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-47	3.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-51	4.56 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-52	4.56 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-43	1.16 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-47	4.56 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-44	1.92 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-45	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-46	3.57 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-46	1.95 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-47	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-48	4.56 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-48	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-44	2.88 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-49	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-48	3.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-50	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-43	1.16 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-51	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-49	4.56 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-52	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-45	4.61 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-44	1.92 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-42	3.92 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-43	4.15 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-44	7.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-44	3.88 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-45	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-46	3.99 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-47	3.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-45	8.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-40	8.57 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-48	3.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-49	3.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-50	3.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-51	3.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-46	7.97 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-52	3.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-42	7.84 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-40	4.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-41	5.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-42	4.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-43	4.61 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-44	4.74 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-47	7.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-45	5.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-46	4.71 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-47	4.68 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-48	4.68 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-48	7.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-49	4.68 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-50	4.68 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-51	4.68 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-52	4.68 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-49	7.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-50	7.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-43	7.83 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-41	0.62 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-40	1.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-51	7.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-41	8.70 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-52	7.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-40	4.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-41	3.73 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-43	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-44	4.62 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-45	5.14 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-46	5.76 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-47	6.18 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-48	6.40 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-49	6.40 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-50	6.40 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-51	6.40 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-52	6.40 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-43	0.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-44	1.03 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-45	2.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-46	2.64 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-47	2.75 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-48	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-49	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-50	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-51	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-52	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-43	2.31 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-44	2.56 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-45	2.57 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-46	2.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-47	2.97 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-48	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-49	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-50	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-51	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-52	2.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-44	0.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-45	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-46	0.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-44	0.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-45	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-46	0.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-45	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-46	0.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-43	0.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-44	0.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-45	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-46	0.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-52	0.22 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-42	2.27 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-41	3.73 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-43	4.82 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-40	4.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-47	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-52	6.23 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-42	4.53 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Ear infection,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-51	6.23 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-50	6.23 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Nasopharyngitis,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-40	1.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-41	0.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-49	6.23 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Bronchitis,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-52	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-48	6.23 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-51	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-50	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-49	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-48	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-47	3.07 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-46	3.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-47	6.13 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-45	3.17 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-44	3.15 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-46	5.99 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-43	2.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-42	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-41	8.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-41	5.59 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Rhinitis,Weeks 40-40	4.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-52	3.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-51	3.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-45	5.78 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Oral herpes,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-50	3.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-49	3.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-48	3.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-47	3.35 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-44	5.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-46	3.30 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-45	2.95 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-40	8.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Hordeolum,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-44	2.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Conjunctivitis,Weeks 40-43	2.31 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Upper respiratory tract infection,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Laryngitis,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Herpes simplex,Weeks 40-46	0.10 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-48	6.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-49	3.70 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-50	3.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-51	2.96 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-52	2.88 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Conjunctivitis,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Conjunctivitis,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Conjunctivitis,Weeks 40-48	4.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Conjunctivitis,Weeks 40-49	2.47 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Conjunctivitis,Weeks 40-50	2.44 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Conjunctivitis,Weeks 40-51	2.22 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Conjunctivitis,Weeks 40-52	2.16 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinitis,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinitis,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinitis,Weeks 40-48	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinitis,Weeks 40-49	1.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinitis,Weeks 40-50	0.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinitis,Weeks 40-51	0.74 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinitis,Weeks 40-52	0.72 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for injury, poisoning and procedural complications.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.00 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	0 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for investigations.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	1.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.98 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	1.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	1.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	1.09 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-42	0.98 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-43	1.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-44	1.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-45	1.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-46	1.09 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-47	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-48	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-49	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-50	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-51	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-52	1.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-46	0.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.58 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.50 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-47	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-52	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-51	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-42	0.50 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.45 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-43	0.58 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-49	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-50	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-44	0.47 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.47 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-48	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Weeks 40-45	0.45 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.38 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	0 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEI listed on the ADR card was decreased appetite.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-47	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-43	0.58 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-44	0.96 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-45	1.77 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-46	1.95 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-48	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-49	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-50	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-51	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-52	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-43	0.58 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-44	0.96 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-45	1.77 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-46	1.95 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-47	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-48	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-49	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-50	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-51	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-52	2.13 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-41	0.62 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-41	0.62 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-42	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-45	6.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-42	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-50	5.30 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-43	8.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-43	8.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-44	8.21 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-52	5.30 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-45	6.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-44	8.21 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-46	5.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-51	5.30 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-47	5.03 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-48	5.30 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-47	5.03 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-49	5.30 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-49	5.30 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-48	5.30 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-50	5.30 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-51	5.30 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-46	5.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-52	5.30 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-52	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-46	2.90 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-46	2.90 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-51	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-47	2.87 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-42	1.01 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-41	0.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-51	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-47	2.87 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-52	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-42	1.01 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-44	2.99 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-50	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-48	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-43	2.50 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-50	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-43	2.50 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-49	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-44	2.99 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-45	3.17 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-41	0.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-45	3.17 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Decreased appetite,Weeks 40-48	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall	Any,Weeks 40-49	3.02 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-47	4.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-48	4.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-49	2.47 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-50	2.44 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-51	2.22 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-52	2.16 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Decreased appetite,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Decreased appetite,Weeks 40-47	4.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Decreased appetite,Weeks 40-48	4.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Decreased appetite,Weeks 40-49	2.47 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Decreased appetite,Weeks 40-50	2.44 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Decreased appetite,Weeks 40-51	2.22 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Decreased appetite,Weeks 40-52	2.16 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were arthropathy and myalgia.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-46	8.77 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-45	8.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-44	8.17 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-43	8.14 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-42	9.93 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-52	3.34 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-51	3.34 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-50	3.34 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-52	8.21 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-49	3.34 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-48	3.34 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-47	3.34 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-46	3.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-51	8.21 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-45	3.19 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-44	3.37 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-43	1.16 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-42	1.42 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	10.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	10.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	10.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	10.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-50	8.21 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	10.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-49	8.21 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	10.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	11.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	10.99 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	11.06 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	9.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-48	8.21 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	11.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-47	8.21 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-41	0.62 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-45	0.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-46	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-47	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-48	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-49	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-50	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-51	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-52	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-46	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-47	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-48	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-49	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-50	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-51	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-52	0.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	5.71 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	6.83 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	5.88 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	6.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	6.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	7.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	8.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	8.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	8.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	8.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	8.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	8.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	8.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-40	1.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-41	1.86 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-42	1.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-43	2.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-44	2.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-45	3.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-46	3.62 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-47	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-48	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-49	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-50	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-51	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-52	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-40	5.71 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-41	5.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-42	4.41 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-43	4.61 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-44	4.74 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-45	5.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-46	5.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-47	5.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-48	5.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-49	5.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-50	5.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-51	5.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-52	5.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	8.39 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-49	2.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-49	6.84 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	8.39 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-50	2.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-44	0.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-51	2.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	8.39 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-52	2.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-43	0.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-44	0.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	8.39 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-45	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-46	0.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	8.39 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-50	6.84 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	6.15 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-46	0.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-48	6.84 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-42	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	7.14 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-51	6.84 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-43	6.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-44	0.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-46	6.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	7.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-45	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-45	1.71 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-47	5.95 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-44	5.13 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-46	1.68 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	7.32 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-47	1.83 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-52	6.84 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-45	5.71 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-48	2.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-50	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-43	6.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-49	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-44	5.98 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-44	0.31 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-48	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-47	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-45	6.46 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-46	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-46	6.69 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-43	0.39 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	5.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	6.83 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-47	6.51 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	8.06 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	7.90 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	8.03 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	8.50 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-48	6.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	8.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	8.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	9.06 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-52	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	9.06 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-49	6.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	9.06 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	9.06 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-51	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	9.06 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-40	1.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-50	6.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-41	1.86 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-41	0.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-42	1.51 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-50	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-43	1.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-44	2.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-51	6.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-45	2.61 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-49	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-46	2.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-47	2.78 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-48	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-48	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-52	6.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-49	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-47	0.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-50	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-51	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-46	0.30 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Weeks 40-52	3.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-40	5.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-41	5.59 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-52	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Weeks 40-42	6.80 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Weeks 40-45	0.34 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Weeks 40-51	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Weeks 40-49	0.09 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-47	4.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-48	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-49	1.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-50	0.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-51	0.74 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-52	0.72 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Arthropathy,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Arthropathy,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Arthropathy,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Arthropathy,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Arthropathy,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Arthropathy,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Arthropathy,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Myalgia,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Myalgia,Weeks 40-47	4.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Myalgia,Weeks 40-48	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Myalgia,Weeks 40-49	1.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Myalgia,Weeks 40-50	0.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Myalgia,Weeks 40-51	0.74 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Myalgia,Weeks 40-52	0.72 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were febrile convulsion and headache.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	8.21 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-47	7.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	8.21 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-45	8.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-42	4.96 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-43	5.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-52	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	8.21 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	8.17 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	8.21 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-48	7.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-51	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-49	7.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	8.21 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	5.67 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-50	7.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-52	7.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	8.21 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-51	7.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-50	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-49	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-44	7.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	8.77 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-48	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-47	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-46	0.97 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-45	1.06 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-46	7.79 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-44	0.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	9.57 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-43	0.58 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	6.40 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	5.71 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	6.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-46	7.25 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	7.61 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	6.83 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-45	6.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-41	6.21 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	7.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-42	5.88 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-43	5.99 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-44	6.03 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	7.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-48	7.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-49	7.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-50	7.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-51	7.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	7.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-52	7.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	6.37 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	7.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	7.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	7.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	6.45 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-47	7.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-40	1.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-41	0.62 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-40	4.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	6.47 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-46	6.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	5.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-45	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-46	0.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-46	0.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-45	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	4.10 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-51	7.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-50	7.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-52	7.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	7.95 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-49	7.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	7.95 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-48	7.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	7.95 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-47	6.18 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-45	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-43	5.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	6.86 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-46	0.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-45	5.71 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	7.95 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-44	4.10 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	6.57 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	7.95 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	6.95 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-48	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	5.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	6.83 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	5.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	6.17 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	6.30 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	7.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	7.69 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	7.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	8.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	8.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	8.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	8.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	8.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-40	4.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-45	6.80 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-46	6.99 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-47	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-48	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-49	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-51	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-44	5.98 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-41	6.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-42	5.04 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-43	5.78 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-47	6.90 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-48	7.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-49	7.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-50	7.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-51	7.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Weeks 40-52	7.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-45	0.45 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-46	0.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-47	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-48	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-49	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-50	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-51	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Weeks 40-52	0.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-40	1.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-41	0.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Weeks 40-51	0.09 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	0 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEI listed on the ADR card was irritability.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-46	0.97 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-47	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-48	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-49	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-50	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.97 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-51	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-52	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-44	0.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-45	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	2.30 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-42	1.47 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-43	1.84 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	2.16 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-44	1.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-45	1.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-46	1.45 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-47	1.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	2.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-48	1.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-49	1.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-50	1.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-51	1.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	1.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-52	1.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	1.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	3.59 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	2.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	2.40 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	2.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	2.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	2.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	2.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	2.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	2.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-43	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-44	3.59 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-45	2.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-46	2.40 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-47	2.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-48	2.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-49	2.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-50	2.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-51	2.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-52	2.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-44	0.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-45	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-46	0.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	1.80 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-52	1.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-51	1.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	1.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-50	1.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-49	1.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-48	1.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-47	1.72 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	2.05 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-46	1.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-45	1.59 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-44	1.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-43	1.73 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-42	1.01 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	1.93 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	1.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	1.26 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	1.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	1.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	1.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	1.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	1.82 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-48	4.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-49	4.94 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-50	3.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-51	2.96 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-52	2.88 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Irritability,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Irritability,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Irritability,Weeks 40-48	4.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Irritability,Weeks 40-49	4.94 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Irritability,Weeks 40-50	3.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Irritability,Weeks 40-51	2.96 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Irritability,Weeks 40-52	2.88 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were cough, dysphonia, epistaxis, nasal congestion, oropharyngeal pain, rhinorrhoea, and wheezing.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	14.59 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-46	3.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	14.59 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	14.59 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	14.94 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	15.60 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-47	3.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-44	0.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	13.94 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	11.63 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-48	3.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-49	1.22 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	9.93 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-49	3.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-50	3.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-51	3.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-52	3.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-47	1.22 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-44	0.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-42	3.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-44	0.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-43	0.58 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-43	5.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-52	9.12 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-44	7.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-51	9.12 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-50	9.12 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-45	9.93 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-49	9.12 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-48	9.12 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-46	9.74 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-47	9.12 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-44	0.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-50	1.22 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-46	0.97 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-51	1.22 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-42	2.84 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-43	2.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-52	1.22 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-44	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-45	3.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-46	3.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-47	3.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-48	1.22 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-48	3.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-45	1.06 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-49	3.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-44	1.44 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-43	1.74 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-50	3.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-42	1.42 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-52	3.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-51	3.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-51	3.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-50	3.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-52	3.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-49	3.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-48	3.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-47	3.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-46	3.57 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-42	3.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-43	0.58 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-45	3.90 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-44	3.37 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-43	3.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-43	3.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-42	2.84 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-44	3.37 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	14.59 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	14.59 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-45	3.19 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	14.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-52	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-46	3.26 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-47	3.24 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-48	3.24 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-49	3.24 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-50	3.24 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-51	3.24 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-52	3.24 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-41	1.24 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-42	1.47 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-43	1.84 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-44	1.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-45	1.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-46	1.45 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-47	1.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-48	1.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-49	1.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-50	1.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-51	1.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-52	1.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-40	5.71 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-41	3.73 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-42	3.92 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-43	4.15 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-44	4.31 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-45	4.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-46	3.62 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-47	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-48	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-49	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-50	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-51	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-52	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-40	5.71 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-41	5.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-42	5.88 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-43	5.53 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-44	5.17 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-45	5.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-47	5.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-48	5.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-49	5.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-50	5.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-51	5.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-52	5.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-40	4.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-41	5.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-42	5.88 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-43	5.53 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-44	5.17 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-45	5.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-46	5.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-47	5.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-48	5.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-49	5.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-50	5.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-51	5.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-52	5.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-43	1.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-44	1.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-46	5.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	8.57 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	11.18 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	10.78 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	11.52 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	11.21 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	12.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	11.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	11.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	11.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	11.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	11.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	11.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	11.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-40	7.14 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-41	4.35 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-42	4.41 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-43	4.15 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-44	3.88 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-45	4.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-46	3.99 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-47	3.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-48	3.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-49	3.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-50	3.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-51	3.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-52	3.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-40	4.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-41	2.48 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-42	3.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-43	3.23 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-44	3.02 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-45	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-42	0.98 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-43	1.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-44	1.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-45	1.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-46	1.09 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-47	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-48	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-49	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-50	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-51	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-52	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-45	1.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-46	1.09 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-47	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-48	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-49	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-50	1.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-51	1.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-49	2.21 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-51	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	22.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-45	4.86 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	22.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	22.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-44	4.62 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-46	2.40 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	22.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-52	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-47	0.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-42	15.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-43	5.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-43	15.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-44	14.36 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-45	10.86 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-46	10.55 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-47	10.53 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-48	10.60 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-52	8.17 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-49	10.60 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-50	10.60 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-51	8.17 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-51	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-51	10.60 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-52	10.60 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-50	8.17 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-48	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-42	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-43	3.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-49	8.17 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-44	2.56 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-45	2.57 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-48	8.17 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-47	8.01 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-48	2.21 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-46	8.15 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-45	8.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-44	10.26 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-52	2.21 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-43	10.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-49	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-42	15.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-43	0.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-44	0.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-51	2.21 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-45	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-52	0.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-46	0.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-47	0.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-51	0.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-48	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-49	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-50	0.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-50	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-51	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-49	0.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-50	2.21 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-50	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-52	0.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-48	0.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-46	9.83 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-47	10.07 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-43	0.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-48	10.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-45	10.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-49	10.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-50	10.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-44	9.74 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-51	10.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-44	1.03 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-52	10.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-47	0.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-43	9.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-45	0.57 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-45	0.57 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-42	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-44	1.03 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-46	0.48 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-52	5.74 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-46	0.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-51	5.74 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-47	0.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-50	5.74 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-47	2.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-49	5.74 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-48	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-45	1.14 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-46	0.48 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-49	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-48	5.74 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	26.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	26.15 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-47	5.26 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	23.59 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-50	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	22.57 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-46	5.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	22.30 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-52	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	22.65 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	22.96 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	17.15 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-49	0.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-45	0.34 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-41	3.73 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	15.22 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-44	0.94 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-40	5.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-41	5.59 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-52	0.85 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-52	0.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-46	0.90 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-47	2.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-45	0.68 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-51	0.85 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-40	4.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-48	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	17.35 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	17.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-45	4.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-50	0.85 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	17.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-50	2.17 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-51	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	17.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-44	4.41 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-43	0.96 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	17.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-52	4.81 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-46	2.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-46	0.30 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	17.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-40	7.14 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-52	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-41	4.35 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-43	4.82 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-49	0.85 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-42	5.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-43	6.74 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-42	4.53 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-47	0.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-48	4.81 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-44	6.93 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-46	0.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-45	6.80 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-41	5.59 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	17.08 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-46	6.59 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-40	5.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-48	2.17 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-47	6.61 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-52	5.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-48	6.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-48	0.85 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-51	4.81 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-49	6.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-51	5.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-42	0.76 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-49	2.17 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-50	6.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	8.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-46	8.59 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-51	6.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-50	5.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Weeks 40-52	6.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-40	4.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	15.91 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-41	2.48 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-47	8.52 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-45	8.73 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	11.18 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-42	2.77 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-49	5.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-46	4.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-48	8.68 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-43	2.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-44	2.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-48	5.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-41	1.24 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-50	4.81 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-45	2.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-49	8.68 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-48	0.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-44	7.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-47	0.86 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-47	5.27 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-47	0.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-42	0.50 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-50	8.68 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-49	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-50	0.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-43	0.58 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-46	5.39 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-51	8.68 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-44	0.47 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-43	6.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-50	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-45	0.34 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-45	5.44 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-52	2.17 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-45	1.02 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-46	0.30 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-52	8.68 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-51	0.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Weeks 40-44	0.47 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-47	0.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-44	5.98 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	12.59 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-48	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-49	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-43	5.39 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-49	4.81 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Weeks 40-47	4.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-50	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-42	0.50 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Weeks 40-42	5.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Weeks 40-44	0.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-51	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Weeks 40-42	5.04 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Weeks 40-43	0.77 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Weeks 40-52	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Weeks 40-51	2.17 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Weeks 40-41	0.00 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-47	13.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-48	25.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-49	18.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-50	13.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-51	14.07 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-52	13.67 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Cough,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Cough,Weeks 40-47	13.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Cough,Weeks 40-48	17.02 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Cough,Weeks 40-49	13.58 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Cough,Weeks 40-50	10.57 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Cough,Weeks 40-51	9.63 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Cough,Weeks 40-52	9.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Dysphonia,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Dysphonia,Weeks 40-47	4.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Dysphonia,Weeks 40-48	6.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Dysphonia,Weeks 40-49	3.70 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Dysphonia,Weeks 40-50	2.44 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Dysphonia,Weeks 40-51	2.22 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Dysphonia,Weeks 40-52	2.16 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Epistaxis,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Epistaxis,Weeks 40-47	4.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Epistaxis,Weeks 40-48	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Epistaxis,Weeks 40-49	1.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Epistaxis,Weeks 40-50	0.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Epistaxis,Weeks 40-51	0.74 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Epistaxis,Weeks 40-52	0.72 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nasal congestion,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nasal congestion,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nasal congestion,Weeks 40-48	6.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nasal congestion,Weeks 40-49	4.94 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nasal congestion,Weeks 40-50	3.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nasal congestion,Weeks 40-51	2.96 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nasal congestion,Weeks 40-52	2.88 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Oropharyngeal pain,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Oropharyngeal pain,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Oropharyngeal pain,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Oropharyngeal pain,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Oropharyngeal pain,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Oropharyngeal pain,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Oropharyngeal pain,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinorrhoea,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinorrhoea,Weeks 40-47	4.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinorrhoea,Weeks 40-48	12.77 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinorrhoea,Weeks 40-49	9.88 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinorrhoea,Weeks 40-50	7.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinorrhoea,Weeks 40-51	7.41 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinorrhoea,Weeks 40-52	7.19 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Wheezing,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Wheezing,Weeks 40-47	4.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Wheezing,Weeks 40-48	4.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Wheezing,Weeks 40-49	2.47 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Wheezing,Weeks 40-50	1.63 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Wheezing,Weeks 40-51	1.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Wheezing,Weeks 40-52	1.44 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Sneezing,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Sneezing,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Sneezing,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Sneezing,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Sneezing,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Sneezing,Weeks 40-51	0.74 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Sneezing,Weeks 40-52	0.72 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were rash and rash generalised.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-47	0.61 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-52	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-45	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-51	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-51	0.61 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-50	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-52	0.61 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-49	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-49	0.61 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-48	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-47	0.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-46	0.97 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-45	1.06 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-50	0.61 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.58 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-44	0.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-48	0.61 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-43	0.58 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	1.95 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-46	0.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	2.16 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-45	1.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-44	1.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-43	1.84 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	2.16 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-42	1.47 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	2.30 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-41	1.24 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-40	1.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	2.16 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	1.86 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	2.16 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	2.86 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-40	1.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-41	0.62 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-42	0.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-43	0.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	2.16 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-44	0.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-45	0.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	2.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	2.17 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-52	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-52	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	1.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-51	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-50	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	2.16 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-49	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-46	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-48	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-47	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-48	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	2.16 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-47	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-49	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-50	0.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-46	1.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-51	0.36 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	1.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	2.05 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	1.71 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	1.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	1.37 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	1.32 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	1.32 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	1.32 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	1.32 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	1.32 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-43	0.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-44	1.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-45	1.14 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-46	0.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-47	0.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-48	0.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-49	0.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-50	0.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-51	0.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-52	0.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-43	0.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-44	0.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-45	0.57 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-46	0.48 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-47	0.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-48	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-49	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-50	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-51	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-52	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-45	0.23 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-52	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-42	0.76 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-47	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-43	0.96 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	1.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-44	0.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	1.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-45	0.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-51	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-46	0.80 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-48	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-47	0.77 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	1.72 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-48	0.75 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	1.80 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-49	0.75 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	1.86 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-50	0.75 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-49	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-51	0.75 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-52	0.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-51	0.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	1.93 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-52	0.75 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-50	0.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-49	0.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-48	0.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-47	0.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	1.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-46	0.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-45	0.68 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	2.86 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-44	0.63 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-43	0.39 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-50	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-42	0.50 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-41	0.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	1.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-45	0.23 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Weeks 40-40	1.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	1.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	1.51 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Weeks 40-46	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-52	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-51	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	1.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-50	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-49	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	1.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-48	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-40	1.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-47	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Weeks 40-41	1.24 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Weeks 40-46	0.20 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-48	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-49	1.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-50	0.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-51	0.74 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Weeks 40-52	0.72 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash,Weeks 40-48	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash,Weeks 40-49	1.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash,Weeks 40-50	0.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash,Weeks 40-51	0.74 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash,Weeks 40-52	0.72 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash generalised,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash generalised,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash generalised,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash generalised,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash generalised,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash generalised,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash generalised,Weeks 40-52	0.00 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for vascular disorders.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.58 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-43	0.58 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-44	0.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-45	0.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-46	0.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-47	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-48	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-49	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-50	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-51	0.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-52	0.30 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-46	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-51	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-52	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-42	0.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-50	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-43	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-49	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-44	0.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-47	0.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-45	0.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Weeks 40-48	0.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Weeks 40-49	0.09 Percentage of subjects

Primary

Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	0 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°2 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	39.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	47.58 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	39.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	39.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	39.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	39.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	39.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	40.11 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	42.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	47.50 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	40.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	29.41 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	46.62 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	46.62 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	46.62 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	46.62 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	46.62 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	46.62 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	45.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	45.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	46.88 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	47.24 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	28.74 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	46.15 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	43.28 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	44.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	44.05 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	44.32 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	47.92 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	48.18 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	48.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	48.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	48.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	48.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	48.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	48.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	25.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	28.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	27.64 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	28.57 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	27.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	28.57 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	28.92 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	28.74 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	28.74 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	28.74 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	28.74 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	28.74 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	52.63 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	43.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	52.63 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	52.63 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	45.72 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	42.11 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	60.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	45.72 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	44.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	46.15 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	56.16 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	42.48 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	45.72 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	52.63 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	52.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	52.63 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	45.72 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	43.68 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	52.63 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	45.72 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	42.48 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	44.23 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	34.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	43.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	46.15 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	34.44 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	46.34 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	45.72 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	35.41 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	45.97 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	43.68 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	46.15 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	45.72 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	49.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	34.69 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	48.58 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	45.72 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	49.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	34.44 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	49.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	45.72 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	34.44 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	49.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	42.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	49.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	45.72 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	49.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	34.44 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	49.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	25.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	34.44 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	28.72 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	43.96 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	34.44 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	27.86 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	46.15 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	31.46 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	44.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	41.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	41.18 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	41.18 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	44.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	44.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	44.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	44.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	44.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	41.18 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	44.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	41.18 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	48.94 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	56.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	44.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	44.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	44.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	41.18 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	41.18 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	44.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	51.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	43.95 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	37.93 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	34.62 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	35.34 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	34.04 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	32.35 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	35.09 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	35.34 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	35.61 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	35.34 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	33.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	35.34 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	36.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	35.48 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	37.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	37.93 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	32.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	35.09 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	37.93 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	34.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	35.34 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	37.93 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	35.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	37.93 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	35.34 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	37.93 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	48.10 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	56.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	45.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	41.48 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	43.94 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	43.32 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	44.49 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	45.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	45.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	45.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	45.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	51.35 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	45.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	49.34 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	47.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	49.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	49.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	49.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	49.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	49.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	38.89 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	44.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	42.04 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	41.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	39.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	43.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	42.80 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	42.80 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	43.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	42.80 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	42.80 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	40.87 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	43.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	42.80 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	34.33 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	42.45 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	35.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	41.77 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	41.83 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	34.04 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	42.41 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	39.65 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	43.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	42.14 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	43.50 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	40.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	43.21 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-47	57.14 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-48	53.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-49	34.62 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-50	29.73 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-51	28.89 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-52	29.17 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-46	50.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-47	40.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-48	41.18 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-49	29.09 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-50	20.93 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-51	21.11 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-52	20.88 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°24 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	1.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	1.23 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	1.19 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	1.14 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	1.04 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	3.85 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	1.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.47 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.45 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.33 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.28 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	1.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	0.88 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.79 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.74 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	1.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	0.88 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.35 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.26 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.22 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Population: Analysis was to be performed on the enrolled subjects vaccinated with a second dose of GSK's quadrivalent seasonal influenza vaccine, and who returned the ADR card, i.e.: only Fluarix Tetra Group subjects who received the second dose. As no AEs were reported for the MedDRA Class considered, the by risk status analysis could not be performed.

Secondary

Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°26 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.56 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.66 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	1.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	3.64 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	1.19 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	1.06 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	3.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	1.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	1.23 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.75 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	1.14 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	3.13 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	0.53 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	0.36 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	0.33 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	0.31 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	0.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	1.12 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	1.12 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	1.06 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	1.12 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	1.12 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	1.12 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	1.12 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.56 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	1.14 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	1.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	0.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.45 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.47 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.66 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	1.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.58 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	0.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	0.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	0.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	0.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	0.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	0.31 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	0.33 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	0.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	0.53 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.55 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	1.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	2.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	2.26 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	2.26 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	1.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	2.26 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	2.26 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	2.26 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	1.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	2.26 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	0.88 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	1.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.79 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	1.47 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	1.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	1.39 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	1.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	2.13 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	1.25 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	1.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	1.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.98 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	1.75 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.66 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	1.67 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.48 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.45 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.45 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.45 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.45 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.45 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.97 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.41 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	0.88 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.91 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.35 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	1.22 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.26 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.95 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	2.13 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.44 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.89 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Secondary

Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°28 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.56 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.66 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	1.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	2.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	1.06 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	2.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	2.26 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	2.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	1.95 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	1.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	1.06 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	1.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	2.14 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	1.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	1.69 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	1.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	1.31 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	1.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	1.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	1.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	1.17 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	1.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	2.27 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.00 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	1.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.79 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	2.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	2.22 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	1.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	1.75 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	1.52 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	1.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	1.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	1.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	1.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	1.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	1.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	1.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	0.88 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.74 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	1.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	0.88 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.35 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	1.22 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.26 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	1.15 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.22 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	1.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.58 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-47	14.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-48	7.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-49	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-50	2.70 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-51	2.22 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-52	2.08 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-50	1.16 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-51	1.11 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-52	1.10 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-47	6.67 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-48	2.94 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-49	1.82 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°4 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	10.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	1.61 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	10.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	10.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	10.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	10.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	10.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	10.17 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	10.60 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	11.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	8.89 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	5.88 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	1.50 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	1.50 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	1.50 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	1.50 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	1.50 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	1.50 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	1.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	1.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	1.56 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	1.57 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	3.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	1.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	3.70 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	4.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	5.68 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	7.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	7.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	7.21 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	7.21 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	7.21 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	7.21 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	7.21 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	7.21 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	2.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	3.19 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	4.88 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	4.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	4.17 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	3.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	3.61 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	3.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	3.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	3.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	3.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	3.59 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	6.14 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	6.81 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	6.14 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	6.14 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	7.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	6.84 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	20.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	7.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	8.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	2.74 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	6.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	7.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	6.14 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	6.31 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	6.14 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	7.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	6.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	6.14 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	7.08 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	6.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	7.69 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	6.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	1.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	3.85 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	7.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	2.44 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	7.08 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	7.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	2.84 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	6.50 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	3.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	7.08 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	3.67 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	7.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	4.83 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	7.08 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	4.75 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	7.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	4.75 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	7.08 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	7.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	4.75 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	6.84 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	4.75 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	7.08 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	4.75 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	7.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	4.75 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	2.27 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	7.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	3.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	6.81 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	7.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	5.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	8.46 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	5.62 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	10.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	12.50 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	10.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	12.05 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	10.83 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	10.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	10.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	10.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	10.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	10.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	10.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	6.82 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	6.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	6.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	3.45 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	6.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	6.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	6.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	3.45 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	6.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	2.99 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	2.63 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	3.45 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	2.42 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	2.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	2.31 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	2.94 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	3.45 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	3.47 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	3.45 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	2.13 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	7.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	7.78 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	3.45 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	7.84 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	7.89 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	6.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	5.26 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	8.33 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	6.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	5.41 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	9.68 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	6.67 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	6.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	6.06 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	8.33 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	6.45 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	6.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	6.67 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	7.17 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	6.61 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	7.17 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	6.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	6.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	7.17 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	7.17 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	6.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	7.17 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	8.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	7.96 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	4.12 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	8.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	4.23 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	2.99 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	8.04 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	2.63 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	4.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	8.04 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	4.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	2.46 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	9.39 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	8.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	8.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	3.77 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	4.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	8.05 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	4.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	3.33 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	8.04 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	2.13 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	3.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	4.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	8.21 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-47	14.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-48	7.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-49	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-50	5.41 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-51	4.44 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-52	4.17 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-46	50.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-47	13.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-48	5.88 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-49	3.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-50	2.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-51	2.22 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-52	2.20 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°6 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	22.96 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	33.06 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	22.96 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	22.96 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	22.96 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	22.96 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	22.96 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	23.16 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	24.50 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	30.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	20.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	17.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	32.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	32.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	32.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	32.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	32.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	32.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	31.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	31.30 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	32.03 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	32.28 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	19.16 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	42.31 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	38.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	39.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	39.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	39.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	41.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	40.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	40.54 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	40.54 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	40.54 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	40.54 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	40.54 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	40.54 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	15.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	20.21 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	19.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	18.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	18.06 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	19.48 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	19.28 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	19.16 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	19.16 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	19.16 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	19.16 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	19.16 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	40.35 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	25.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	40.35 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	40.35 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	26.84 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	23.68 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	40.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	26.84 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	26.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	26.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	43.84 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	23.86 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	26.84 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	40.35 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	39.64 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	40.35 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	26.84 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	23.83 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	40.35 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	26.84 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	23.86 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	26.92 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	22.32 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	38.81 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	42.31 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	21.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	35.61 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	26.84 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	21.97 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	35.07 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	23.83 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	35.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	26.84 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	37.67 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	21.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	36.93 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	26.84 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	37.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	21.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	37.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	26.84 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	21.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	37.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	23.68 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	37.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	26.84 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	37.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	21.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	37.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	15.91 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	21.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	20.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	25.08 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	21.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	19.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	26.92 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	19.10 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e. week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	30.40 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	30.40 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	24.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	24.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	30.40 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	30.40 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	30.40 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	30.40 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	24.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	24.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	24.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	30.40 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	30.40 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	24.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	25.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	30.40 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	30.40 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	32.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	25.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	30.40 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	24.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	37.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	28.28 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	27.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	28.68 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	28.47 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	28.28 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	28.28 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	28.28 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	28.28 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	28.28 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	28.35 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	27.07 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	26.87 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	28.95 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	29.03 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	25.53 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	25.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	24.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	24.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	27.19 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	27.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	27.07 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	27.07 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	27.07 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	27.07 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	27.07 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	34.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	25.99 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	43.75 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	32.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	26.67 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	26.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	19.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	26.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	26.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	34.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	24.75 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	26.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	32.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	34.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	22.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	26.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	24.73 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	34.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	24.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	34.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	32.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	31.50 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	28.93 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	28.93 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	26.87 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	28.95 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	28.93 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	28.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	26.92 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	25.53 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	28.93 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	29.46 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	27.77 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	26.44 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	28.42 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	27.76 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	27.37 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	28.37 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	28.93 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	27.77 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	27.45 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	28.12 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	28.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	28.15 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	28.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	28.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	28.00 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-47	28.57 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-48	15.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-49	11.54 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-50	10.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-51	8.89 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-52	10.42 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-47	33.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-48	17.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-49	10.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-50	8.14 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-51	8.89 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-52	8.79 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°8 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.56 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.66 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.33 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.18 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.18 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.24 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.18 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.18 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.18 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.18 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Secondary

Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°10 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	7.14 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	7.14 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	7.14 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	7.14 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	7.14 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	7.14 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	7.34 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	7.95 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	6.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	4.44 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.79 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	5.99 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	11.54 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	11.94 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	9.88 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	10.71 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	11.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	11.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	10.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	10.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	10.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	10.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	10.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	10.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	10.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	6.82 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	6.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	6.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	6.02 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	5.56 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	5.84 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	6.02 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	5.99 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	5.99 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	5.99 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	5.99 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	5.99 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	8.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	5.26 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	8.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	8.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	5.60 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	4.74 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	5.60 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	8.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	4.58 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	5.60 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	8.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	9.01 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	8.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	5.60 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	4.33 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	8.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	5.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	4.58 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	1.92 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	5.80 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	11.94 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	11.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	6.61 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	4.39 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	5.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	6.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	4.74 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	4.33 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	4.98 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	5.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	6.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	6.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	6.53 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	5.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	6.42 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	6.61 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	6.42 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	5.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	6.61 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	6.42 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	4.74 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	6.42 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	5.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	6.42 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	6.61 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	6.42 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	6.82 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	6.61 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	6.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	5.26 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	6.61 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	5.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	3.85 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	5.62 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	6.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	4.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	6.02 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	7.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	7.10 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	6.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	6.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	6.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	6.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	6.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	8.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	8.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	8.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	7.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	8.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	8.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	8.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	7.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	8.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	8.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	8.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	7.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	8.06 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	7.87 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	8.09 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	7.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	7.64 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	7.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	8.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	7.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	7.78 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	7.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	7.84 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	7.89 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	6.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	5.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	5.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	5.41 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	3.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	4.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	5.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	4.55 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	4.61 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	5.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	7.14 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	7.62 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	5.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	7.62 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	5.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	5.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	7.62 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	7.62 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	7.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	7.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	7.50 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	7.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	4.53 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	7.50 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	4.83 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	8.96 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	6.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	8.77 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	4.80 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	7.31 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	4.80 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	3.86 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	6.53 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	7.50 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	7.50 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	4.06 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	4.80 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	6.32 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	4.80 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	4.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	7.09 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	8.51 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	4.58 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	4.80 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	7.50 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-48	23.08 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-49	11.54 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-50	8.11 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-51	6.67 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-52	6.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-50	1.16 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-51	1.11 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-52	1.10 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°30 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	1.04 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.33 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.74 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.22 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Secondary

Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°32 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.56 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.66 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	1.23 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	2.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	2.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	2.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	1.82 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	1.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.75 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.60 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	0.45 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.66 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.95 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.90 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.67 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.58 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.56 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.56 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.56 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.56 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.56 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.56 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.56 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.49 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	2.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	2.26 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	2.26 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	2.26 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	2.26 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	2.26 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	2.26 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	2.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	3.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	2.94 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	2.63 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.78 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	1.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.73 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	1.22 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	1.72 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.95 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.71 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Secondary

Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°12 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	3.06 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	3.06 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	3.06 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.79 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	3.06 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	2.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	3.06 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	3.06 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	2.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	1.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	1.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	1.19 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	1.14 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	1.23 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	1.04 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	6.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	8.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	7.89 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	20.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	1.37 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.90 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	7.58 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	6.86 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	6.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	6.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	6.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	6.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	6.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.88 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.84 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.84 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.84 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.84 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.95 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.98 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	1.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	0.45 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	6.78 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	6.78 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	1.31 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	6.78 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.84 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	1.46 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	6.78 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	6.78 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	1.65 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	6.50 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	6.86 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	1.65 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	7.58 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.84 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	1.65 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.85 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	1.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	1.65 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	1.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	7.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	1.65 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	8.46 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	3.85 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	1.65 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	3.43 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	6.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	2.41 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	3.18 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	3.28 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	3.43 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	3.43 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	3.43 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	3.43 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	3.43 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	0.88 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.79 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.74 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	6.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	6.58 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	2.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	5.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	5.41 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	9.68 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	7.41 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	5.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	6.06 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	10.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	5.53 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	5.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	4.76 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	5.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	5.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	5.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	5.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	5.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	5.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	5.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	5.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	3.39 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	3.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	2.67 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	3.39 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	2.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	1.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	0.88 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	2.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	3.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	2.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	3.27 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	3.39 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	3.39 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	2.90 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	2.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	1.72 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	2.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	2.82 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	3.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	2.83 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	2.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	3.39 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-50	2.70 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-51	2.22 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-52	2.08 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-47	6.67 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-48	5.88 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-49	3.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-50	2.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-51	2.22 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-52	2.20 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°14 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	12.90 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	12.03 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	9.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	9.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	9.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	9.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	9.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	9.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	10.17 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	9.93 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	8.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	12.03 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	12.03 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	12.03 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	12.03 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	12.03 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	12.21 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	12.21 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	12.50 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	12.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	7.19 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	8.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	7.41 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	7.14 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	7.95 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	8.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	10.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	9.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	9.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	9.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	9.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	9.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	9.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	6.82 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	5.32 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	4.88 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	6.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	6.25 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	7.14 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	7.23 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	7.19 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	7.19 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	7.19 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	7.19 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	7.19 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	6.49 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	4.95 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	6.49 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	14.04 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	5.79 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	6.49 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	5.05 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	20.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	14.04 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	4.90 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	15.07 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	14.04 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	6.49 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	14.04 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	14.41 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	6.49 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	14.04 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	14.04 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	7.14 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	3.85 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	5.05 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	8.96 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	8.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	10.73 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	6.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	8.52 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	10.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	10.86 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	6.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	7.69 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	11.67 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	8.75 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	12.22 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	6.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	8.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	5.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	12.01 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	8.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	12.01 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	6.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	12.01 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	12.01 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	12.01 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	4.95 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	8.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	12.01 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	7.69 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	6.82 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	8.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	5.32 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	8.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	4.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	4.90 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	5.06 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	6.49 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	9.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	6.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	9.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	10.19 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	10.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	9.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	9.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	9.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	9.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	9.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	12.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	12.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	12.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	12.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	12.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	12.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	12.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	12.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	12.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	12.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	12.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	6.82 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	6.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	6.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	9.66 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	6.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	6.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	6.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	9.66 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	6.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	5.97 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	8.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	9.66 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	8.06 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	8.66 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	8.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	8.82 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	9.66 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	9.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	9.66 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	2.13 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	2.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	4.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	9.66 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	4.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	6.14 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	12.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	7.89 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	5.56 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	6.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	8.11 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	7.53 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	5.93 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	6.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	6.57 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	6.67 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	6.91 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	6.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	7.62 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	9.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	7.05 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	9.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	6.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	6.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	9.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	9.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	8.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	9.87 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	9.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	8.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	9.05 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	9.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	9.05 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	5.97 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	4.46 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	8.77 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	9.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	8.23 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	9.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	9.47 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	6.94 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	9.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	9.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	9.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	9.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	4.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	9.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	8.72 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	8.27 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	2.13 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	8.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	9.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	9.11 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-47	6.67 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-48	2.94 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-49	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-50	1.16 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-51	1.11 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-52	1.10 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°16 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	10.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	4.84 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	10.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	10.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	10.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	10.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	10.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	11.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	13.91 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	13.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	11.11 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	11.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	4.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	4.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	4.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	4.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	4.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	4.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	4.58 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	4.58 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	4.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	4.72 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	4.19 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	10.45 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	8.64 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	9.52 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	10.23 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	10.42 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	12.73 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	13.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	13.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	13.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	13.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	13.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	13.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	4.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	4.26 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	4.88 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	4.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	4.17 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	4.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	4.22 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	4.19 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	4.19 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	4.19 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	4.19 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	4.19 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	13.16 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	4.64 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	13.16 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	13.16 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	6.19 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	4.21 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	6.19 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	5.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	13.70 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	4.58 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	6.19 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	13.16 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	13.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	13.16 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	6.19 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	4.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	13.16 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	6.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	4.58 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	1.92 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	7.59 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	10.45 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	7.69 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	7.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	6.34 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	6.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	9.18 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	6.64 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	4.69 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	6.79 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	6.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	8.67 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	8.16 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	9.94 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	6.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	10.06 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	7.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	10.06 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	6.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	7.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	10.06 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	4.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	10.06 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	6.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	10.06 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	7.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	10.06 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	4.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	7.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	4.26 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	4.64 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	7.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	5.71 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	5.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	6.18 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	11.27 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	25.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	14.89 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	15.66 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	14.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	12.57 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	11.27 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	11.27 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	11.27 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	11.27 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	11.27 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	3.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	3.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	3.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	3.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	3.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	3.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	3.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	3.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	3.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	3.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	3.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	8.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	8.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	8.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	7.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	8.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	8.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	8.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	7.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	8.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	5.97 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	6.14 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	7.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	5.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	5.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	5.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	5.88 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	7.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	6.94 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	7.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	8.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	7.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	7.78 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	7.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	7.84 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	7.89 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	6.58 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	2.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	7.39 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	5.41 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	5.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	3.70 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	7.39 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	6.57 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	6.91 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	7.39 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	6.67 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	8.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	7.05 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	8.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	7.39 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	7.39 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	8.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	8.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	7.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	8.52 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	9.46 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	9.32 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	5.97 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	9.46 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	6.24 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	5.97 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	8.93 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	6.14 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	6.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	8.78 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	6.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	4.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	9.80 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	9.46 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	9.46 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	4.64 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	6.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	9.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	6.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	4.10 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	9.93 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	8.51 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	5.45 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	6.40 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	9.46 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Secondary

Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°18 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	1.32 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	1.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	1.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	1.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	1.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	1.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	1.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	1.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	1.53 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	1.23 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	1.19 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	2.41 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	1.14 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	1.04 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	2.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	3.01 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	2.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	2.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	2.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	2.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	2.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	2.40 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	2.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	2.78 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.90 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	3.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	3.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	3.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	3.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	3.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	3.68 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	2.89 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	3.27 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	3.41 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	1.92 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	3.24 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	3.24 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	3.27 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	3.24 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	3.24 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	3.85 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	2.23 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	3.41 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	2.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	1.93 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	1.93 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	1.93 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	1.93 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	2.14 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	1.93 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	1.93 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	2.25 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.33 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	2.04 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.45 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.47 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	1.97 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	3.68 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	3.24 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	1.47 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	1.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	1.27 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	1.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	1.47 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	1.47 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	1.47 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	1.47 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	1.47 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	3.79 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	3.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	3.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	3.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	3.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	3.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	3.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	5.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	5.56 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	4.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	4.39 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.66 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	2.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	3.48 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	5.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	4.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	3.48 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	3.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	1.67 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	3.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	3.48 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	1.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	1.35 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	3.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	1.35 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	3.48 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	3.48 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	1.35 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	1.35 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	1.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	1.35 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	1.96 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	1.94 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	1.65 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	1.96 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	1.61 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	3.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	1.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	2.01 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	1.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.35 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	2.86 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	1.96 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	1.96 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	1.45 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	1.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	2.87 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	1.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	1.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	1.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	1.53 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	1.60 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	1.96 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-48	5.88 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-49	7.27 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-50	4.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-51	4.44 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-52	4.40 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°20 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	17.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	9.68 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	17.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	17.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	17.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	17.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	17.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	18.64 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	20.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	20.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	15.56 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	11.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	9.77 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	9.77 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	9.77 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	9.77 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	9.77 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	9.77 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	9.92 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	9.92 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	10.16 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	10.24 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	7.78 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	15.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	16.42 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	16.05 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	16.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	17.05 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	17.71 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	17.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	17.12 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	17.12 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	17.12 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	17.12 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	17.12 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	17.12 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	4.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	7.45 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	7.32 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	8.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	7.64 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	8.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	7.83 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	7.78 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	7.78 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	7.78 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	7.78 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	7.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	20.18 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	23.53 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	20.18 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	20.18 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	23.89 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	23.68 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	20.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	23.89 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	26.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	26.15 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	19.18 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	22.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	23.89 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	20.18 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	20.72 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	20.18 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	23.89 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	23.47 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	20.18 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	23.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	22.88 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	26.92 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	12.05 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	16.42 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	15.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	13.22 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	12.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	23.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	14.43 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	12.80 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	23.47 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	13.12 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	23.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	14.67 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	13.41 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	15.63 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	23.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	15.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	13.22 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	15.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	23.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	13.22 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	15.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	23.68 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	15.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	23.89 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	15.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	13.22 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	15.36 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	4.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	13.22 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	7.45 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	23.53 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	13.22 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	7.86 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	26.15 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	10.11 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	17.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	12.50 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	17.02 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	20.48 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	20.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	18.58 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	17.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	17.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	17.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	17.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	17.65 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	9.60 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	9.60 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	9.60 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	9.60 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	9.60 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	9.60 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	9.60 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	9.60 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	9.60 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	9.60 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	9.60 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	12.12 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	12.03 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	12.03 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	11.03 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	12.03 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	12.03 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	12.03 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	11.03 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	12.03 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	8.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	12.28 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	11.03 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	12.10 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	11.81 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	11.54 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	11.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	11.03 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	11.03 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	8.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	8.75 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	11.03 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	10.78 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	12.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	31.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	23.03 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	25.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	23.04 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	29.73 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	24.73 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	22.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	23.04 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	22.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	26.67 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	22.12 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	23.04 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	22.86 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	22.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	22.47 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	22.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	23.04 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	23.04 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	22.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	22.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	22.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	22.87 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	18.39 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	18.45 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	15.64 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	18.39 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	15.90 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	8.96 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	12.50 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	12.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	16.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	18.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	16.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	12.63 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	17.96 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	18.39 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	18.39 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	14.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	16.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	16.67 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	16.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	14.62 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	19.15 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	8.51 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	15.69 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	16.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	18.39 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-47	28.57 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-48	30.77 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-49	23.08 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-50	18.92 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-51	20.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-52	18.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-47	6.67 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-48	23.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-49	16.36 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-50	11.63 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-51	11.11 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-52	10.99 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°22 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	3.06 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	3.06 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	3.06 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	3.06 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	3.06 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	3.06 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	3.39 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	3.97 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	1.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	2.22 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	2.99 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	4.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	3.19 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	3.25 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	3.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	3.47 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	3.25 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	3.01 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	2.99 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	2.99 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	2.99 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	2.99 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	2.99 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	1.86 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	1.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	2.11 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	1.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	1.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	1.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	1.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	1.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	2.17 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	1.77 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	1.96 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	3.85 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	2.68 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	3.03 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	1.77 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	3.61 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	2.17 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	1.77 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	3.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	1.77 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	3.03 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	1.77 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	3.03 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	2.11 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	1.77 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	3.03 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	4.55 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	3.03 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	3.19 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	1.86 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	3.03 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	2.86 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	1.54 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	3.37 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	2.94 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	2.94 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	2.94 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	2.94 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	2.94 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	1.20 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	3.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	3.28 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	2.94 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	2.13 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	1.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	1.61 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	1.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	1.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	2.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	2.22 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	1.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	1.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	1.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	2.99 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	1.75 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	1.75 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	2.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	2.31 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	2.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	2.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	2.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	2.21 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	1.52 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	2.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	2.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	2.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	1.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	2.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	2.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	12.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.51 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	2.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	2.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	2.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	2.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	3.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.43 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	2.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	5.41 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.74 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	2.24 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	2.99 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	1.75 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	2.87 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.70 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	2.38 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.87 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	1.03 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.87 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	2.45 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	1.03 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	1.01 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	1.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	1.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	3.07 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	1.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	1.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	1.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	2.13 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	2.32 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	3.57 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	2.32 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	2.52 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	2.32 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	2.32 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	2.32 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-48	2.94 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-49	1.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-50	1.16 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-51	1.11 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Weeks 40-52	1.10 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°34 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.75 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.79 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-42	0.49 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-43	0.47 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-44	0.45 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-51	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-45	0.33 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-46	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-47	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-48	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-49	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-47	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-49	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-50	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-48	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-51	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-48	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	18-65 years,Weeks 40-52	0.28 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-51	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-47	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-49	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	6 months to 17 years,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category	>65 years,Weeks 40-43	0.00 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The cumulative percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.80 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-52	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-46	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-46	0.21 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-51	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-47	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-42	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-51	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-47	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-52	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-42	0.35 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-44	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-50	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-48	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-43	0.29 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-50	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-43	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-49	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-44	0.26 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-40	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-45	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-41	0.00 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-45	0.22 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Weeks 40-48	0.20 Percentage of subjects
Total Group	Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Weeks 40-49	0.00 Percentage of subjects

Secondary

Cumulative Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Secondary

Weekly Percentage of Subjects Reporting Any AEIs and/or AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Week 46	33.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Week 47	47.37 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Week 48	44.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Week 49	11.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Week 50	9.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Week 51	25.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Week 52	25.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 43	45.16 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 44	55.56 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 47	38.10 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 46	26.92 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 42	45.39 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 45	35.14 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 46	42.31 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 41	36.26 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 47	50.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 40	32.86 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 43	38.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 44	20.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 42	32.56 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 45	66.67 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 44	35.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 42	44.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 47	70.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 46	38.81 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 43	47.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 48	81.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 45	50.97 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 48	81.25 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 40	32.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 41	36.26 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 42	42.80 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 43	45.90 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 44	39.66 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 45	47.37 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 46	36.97 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEIs and/or Other Aes, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Week 47	53.49 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°36 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	29.41 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	100 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	36.62 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	31.58 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	57.14 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	47.58 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	46.43 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	33.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	26.92 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	50.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	24.14 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	9.09 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	46.15 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	50.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	41.46 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	40.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	87.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	32.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	50.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	50.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	25.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	33.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	100 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	33.33 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	66.67 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	47.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	33.33 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	47.13 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	31.03 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	70.59 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	81.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	60.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	55.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	44.74 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	44.23 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	83.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	46.15 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	25.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	56.96 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	32.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	50.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	33.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	26.09 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	47.83 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	41.46 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	44.74 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	46.15 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	81.25 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	45.65 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	70.59 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	31.03 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	38.27 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	47.13 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	33.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	28.95 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	47.44 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	44.23 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	30.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at any point from dose 1 vaccination (i.e., week 40) up to the end of the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	35.14 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	55.56 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	56.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	44.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	26.92 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	38.10 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	45.16 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	36.36 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	25.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	50.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	58.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	33.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	38.89 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	40.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	30.30 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	100 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	83.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	36.17 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	34.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	40.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	35.71 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	56.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	47.62 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	34.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	52.17 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	39.58 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	70.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	76.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	38.89 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	47.37 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	49.21 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	36.84 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	70.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	100 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	42.69 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	45.51 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	46.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	43.66 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	45.16 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	33.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	43.08 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	100 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	52.17 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	36.36 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	72.73 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	34.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	76.92 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	36.17 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	46.88 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	35.87 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any AEs, Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	40.74 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 47	66.67 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 48	50.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 49	15.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 50	18.18 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 51	25.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 52	33.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 46	50.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 47	38.46 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 48	42.11 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 49	9.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 50	6.45 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 51	25.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 52	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°58 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	3.85 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	1.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	1.49 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Secondary

Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°60 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	2.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	2.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	25.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	2.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	7.14 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	1.67 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	1.92 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	2.53 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	2.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	2.44 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	2.17 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	1.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	2.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	8.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	5.56 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	16.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	2.13 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	4.35 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.56 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	2.82 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	1.45 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	2.27 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	2.13 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	1.09 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were diarrhoea, nausea, and vomiting. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Secondary

Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°62 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	2.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	2.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	6.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	4.35 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	2.17 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	2.27 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	1.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	6.06 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	1.41 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	1.49 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	3.08 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 47	16.67 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 47	7.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 52	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	9.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	9.68 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	13.89 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	9.46 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	7.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	12.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	16.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	10.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	8.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	2.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	8.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	15.15 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	2.13 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	12.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	2.99 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	6.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	4.76 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	13.04 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	3.26 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	10.42 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	10.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	15.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	8.33 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	10.53 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	4.76 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	10.53 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	10.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	2.34 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	12.68 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	11.11 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	10.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	8.06 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	2.27 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	12.31 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	5.80 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	15.38 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	2.99 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	9.38 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	2.13 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	7.61 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	6.18 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	9.09 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were diarrhoea, nausea, and vomiting. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 47	16.67 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 50	9.09 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 46	50.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 47	7.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 52	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	17.57 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	41.67 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	37.50 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	30.40 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	15.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	28.57 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	19.35 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	27.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	25.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	25.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	50.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	27.78 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	30.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	24.24 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	50.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	31.91 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	26.87 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	20.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	19.05 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	43.75 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	23.81 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	17.39 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	35.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	29.17 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	50.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	61.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	19.44 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	28.07 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	28.57 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	26.32 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	50.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	66.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	28.07 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	29.21 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	26.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	30.99 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	20.97 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	17.78 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	32.31 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	66.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	30.43 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	27.27 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	45.45 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	26.87 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	61.54 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	31.91 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	34.38 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	25.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	25.93 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 47	33.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 49	7.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 50	9.09 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 52	33.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 47	38.46 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 48	5.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 50	3.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 51	25.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 52	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	1.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.56 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Secondary

Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°44 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	9.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	5.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	8.57 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	7.14 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	6.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	11.54 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	25.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	12.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	12.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	6.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	7.14 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	10.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	6.82 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	33.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	8.33 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	5.13 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	6.67 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	3.45 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	6.90 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	17.65 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	12.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	8.82 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	10.53 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	1.92 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	9.62 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	6.82 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	8.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	6.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	10.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	16.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	4.35 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.72 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	12.20 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	5.26 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	11.54 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	12.50 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	6.52 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	17.65 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	6.90 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	9.88 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	3.45 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	6.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	5.26 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	5.13 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	1.92 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	5.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	9.46 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	8.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	4.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	6.45 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	9.09 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	8.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	8.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	6.06 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	16.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	8.51 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	8.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	10.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	7.14 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	6.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	4.76 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	4.35 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	6.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	10.42 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	10.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	15.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	5.26 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	4.76 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	5.26 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	20.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.58 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	7.87 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	5.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	7.04 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	6.45 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	6.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	4.62 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	5.80 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	9.09 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	18.18 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	8.96 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	15.38 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	8.51 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	6.25 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	8.70 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	3.70 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 48	50.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 50	3.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 52	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°64 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	12.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	1.27 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	16.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	1.45 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Injury, Poisoning and Procedural Complications (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were diarrhoea, nausea, and vomiting. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Secondary

Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°66 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	1.41 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	7.14 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	3.45 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	33.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	16.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	2.17 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.72 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	1.23 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	1.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	6.06 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	10.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.56 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	1.61 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	3.08 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Investigations (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Secondary

Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°46 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	5.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	4.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	2.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	2.44 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	11.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	6.67 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	6.90 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	12.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	20.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	2.44 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	6.90 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	6.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.72 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	11.54 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	3.85 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	5.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	10.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	2.63 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	3.70 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	2.17 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	12.50 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	4.05 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	6.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	4.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	2.13 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	2.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	6.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	4.76 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	17.39 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	4.35 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	15.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	2.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	14.04 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	3.17 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.58 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	3.93 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	13.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	7.04 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	1.61 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	2.22 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	3.08 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	2.90 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	15.38 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	2.13 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	3.13 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	1.09 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 50	9.09 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 47	7.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 48	5.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Metabolism and Nutrition Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 52	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°48 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	11.27 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	5.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	20.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	12.90 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	11.54 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	3.45 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	25.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	12.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	30.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	12.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	4.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	21.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	20.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	6.82 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	8.33 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	1.67 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	3.45 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	3.45 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	5.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	37.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	20.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	14.71 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	13.16 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	7.69 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	15.38 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	6.82 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	13.92 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	4.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	20.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	2.17 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	11.59 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	12.20 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	7.89 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	3.85 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	37.50 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	15.22 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	5.88 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	3.45 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	12.35 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	3.45 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	1.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	10.53 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	7.69 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	7.69 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	5.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	10.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	19.44 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	6.25 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	12.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	11.54 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	4.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	2.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	8.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	25.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	16.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	33.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	3.03 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	16.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	12.77 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	5.97 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	20.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	2.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	12.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	4.76 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	4.35 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	8.70 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	8.33 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	46.15 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	5.56 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	8.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	7.94 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	10.53 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	10.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	9.94 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	10.11 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	10.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	12.68 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	4.84 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	2.22 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	6.15 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	8.70 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	2.27 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	9.09 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	5.97 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	46.15 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	12.77 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	3.13 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	9.78 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	14.81 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 47	7.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Musculoskeletal and Connective Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 52	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°50 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	14.08 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	10.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	4.84 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	17.14 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	11.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	12.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	6.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	33.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	25.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	4.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	12.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	10.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	4.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	28.57 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	100 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	5.75 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	1.67 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	3.45 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	5.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	37.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	14.71 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	13.16 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	16.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	13.92 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	4.55 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	10.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	4.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	16.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	4.35 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	8.70 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	12.20 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	7.69 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	7.89 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	37.50 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	5.88 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	13.04 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	3.45 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	5.75 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	13.58 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	1.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	7.69 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	1.92 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	17.31 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	9.68 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	25.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	16.67 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	13.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	3.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	8.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	9.09 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	6.06 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	100 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	8.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	5.97 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	25.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	16.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	6.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	10.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	9.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	4.35 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	7.61 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	8.33 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	38.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	2.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	7.02 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	12.70 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	10.53 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	10.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	33.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	5.97 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	9.09 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	13.04 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	38.46 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	11.27 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	14.81 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	9.68 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	18.18 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	9.23 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	33.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	6.52 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	2.92 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	6.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	6.38 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	10.11 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Nervous System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Secondary

Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°52 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	1.41 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	2.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	7.14 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	10.34 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	10.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	5.13 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	3.33 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	1.15 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	6.90 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	5.88 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	1.92 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	6.52 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.72 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	2.63 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	2.17 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	5.88 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	6.90 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	1.23 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	1.15 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	3.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	2.63 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	5.13 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	1.92 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	1.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	12.12 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	10.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	2.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	4.35 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	2.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	10.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	2.78 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	7.02 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	1.59 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	5.26 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.58 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.56 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	6.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	2.82 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	1.61 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	2.22 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	6.15 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	1.45 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	3.13 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	2.17 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	3.70 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 48	10.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 49	9.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Psychiatric Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 52	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°54 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	11.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	21.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	10.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	25.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	9.68 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	17.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	33.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	14.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	6.90 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	15.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	25.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	17.07 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	20.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	25.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	10.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	14.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	20.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	4.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	33.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	25.64 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	18.33 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	22.99 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	17.24 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	35.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	31.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	20.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	19.12 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	23.68 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	26.92 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	21.15 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	4.55 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	18.99 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	10.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	20.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	33.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	8.70 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	10.14 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	17.07 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	18.42 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	15.38 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	31.25 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	19.57 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	35.29 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	17.24 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	20.99 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	22.99 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	18.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	5.26 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	25.64 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	26.92 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	10.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	20.27 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	25.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	12.50 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	9.60 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	7.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	9.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	19.35 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	9.09 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	8.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	25.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	10.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	9.09 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	16.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	17.02 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	8.96 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	30.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	16.67 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	31.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	28.57 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	21.74 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	20.65 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	20.83 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	30.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	23.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	25.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	24.56 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	22.22 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	21.05 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	30.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	66.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	12.87 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	20.79 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	23.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	21.13 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	24.19 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	15.56 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	15.38 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	66.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	21.74 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	9.09 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	27.27 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	8.96 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	23.08 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	17.02 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	15.63 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	15.22 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	14.81 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 47	33.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 48	33.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 49	15.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 50	9.09 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 51	25.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 47	7.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 48	36.84 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 49	4.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 50	3.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Respiratory, Thoracic and Mediastinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 52	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°56 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	7.04 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	3.57 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	3.45 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	10.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	2.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	7.14 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	4.55 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	3.33 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	2.30 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	3.85 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	1.92 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	4.55 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	2.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	2.17 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	5.26 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	6.17 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	2.30 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	3.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	3.85 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	6.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	3.23 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	2.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	12.50 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	33.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	3.03 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	2.99 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	2.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	12.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	4.35 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	2.17 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	3.93 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	1.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	1.41 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	1.61 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	2.22 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	4.62 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	2.27 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	2.99 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	3.70 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	At risk,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 48	5.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Skin and Subcutaneous Tissue Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status	Not at risk,Week 52	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°68 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.72 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Risk status (At risk; Not at risk) was recorded for influenza-associated morbidity and mortality as per healthcare professional assessment.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.80 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 42	0.58 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	At risk,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status	Not at risk,Week 46	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Any Vascular Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Secondary

Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for cardiac disorders.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 40	1.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	1.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	1.43 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 40	1.43 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tachycardia,Week 47	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. There were no predefined AEIs listed on the ADR card for cardiac disorders.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	0 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for ear and labyrinth disorders.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	2.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 46	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 41	1.10 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 41	1.10 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 45	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	1.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 44	1.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 44	0.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 41	1.10 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 46	0.84 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tinnitus,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	2.20 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 45	0.81 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.84 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	1.72 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vertigo,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 41	1.10 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.81 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pain,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear haemorrhage,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear pruritus,Week 44	0.86 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. There were no predefined AEIs listed on the ADR card for ear and labyrinth disorders.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	0 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for eye disorders.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 42	2.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	1.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 40	1.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	4.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 42	2.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	1.43 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.85 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 42	0.42 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye discharge,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 40	1.43 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Eye pruritus,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 42	0.42 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lacrimation increased,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 44	0.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Swelling of eyelid,Week 47	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. There were no predefined AEIs listed on the ADR card for eye disorders.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Eye pruritus,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 47	10.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Eye pruritus,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Eye pruritus,Week 47	10.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Eye pruritus,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Eye pruritus,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Eye pruritus,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Eye pruritus,Week 52	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were diarrhoea, nausea, and vomiting.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 45	2.70 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 46	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 45	2.70 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 47	9.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 43	6.45 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	9.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 43	3.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	7.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	9.46 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 46	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	13.89 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	9.68 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 45	5.41 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 44	8.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 43	3.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 42	2.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 45	5.56 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 42	2.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 42	2.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 42	2.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	2.86 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	2.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	11.63 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	6.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 40	2.86 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 41	2.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 42	6.98 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 44	6.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 45	5.56 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 41	1.10 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 42	4.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 43	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 46	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 42	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 43	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 42	5.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 43	2.56 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 48	6.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 44	3.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 45	1.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 47	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	8.97 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 46	1.49 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 44	3.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	4.62 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 46	5.97 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	3.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	10.45 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	10.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	12.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 43	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 47	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 42	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 43	5.13 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 44	3.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 45	3.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 46	5.97 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 45	1.94 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 48	6.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 46	1.49 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	6.07 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 46	5.04 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 46	4.20 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	8.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 46	0.84 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	9.30 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	12.50 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 40	2.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 48	6.25 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 41	2.20 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 47	6.98 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 42	0.42 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 42	2.12 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 44	2.59 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 42	0.42 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 43	2.46 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 43	4.92 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 42	2.97 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 48	6.25 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 44	3.45 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 43	3.28 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 43	3.28 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 42	0.42 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 41	1.10 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 42	1.69 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Diarrhoea,Week 45	3.24 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 44	4.31 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 47	2.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tongue discomfort,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 45	2.02 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	2.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	2.20 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nausea,Week 45	2.43 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Vomiting,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	5.08 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal discomfort,Week 46	0.84 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Stomatitis,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Gingival bleeding,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	9.02 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Abdominal pain,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Lip swelling,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	7.76 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were diarrhoea, nausea, and vomiting.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Abdominal pain,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 46	33.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 47	10.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 50	2.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Diarrhoea,Week 46	33.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Diarrhoea,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Diarrhoea,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Diarrhoea,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Diarrhoea,Week 50	2.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Diarrhoea,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Diarrhoea,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nausea,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nausea,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nausea,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nausea,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nausea,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nausea,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nausea,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Vomiting,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Vomiting,Week 47	5.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Vomiting,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Vomiting,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Vomiting,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Vomiting,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Vomiting,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Abdominal pain,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Abdominal pain,Week 47	5.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Abdominal pain,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Abdominal pain,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Abdominal pain,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Abdominal pain,Week 52	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°38 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	5.88 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	9.86 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	10.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	14.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	1.61 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	10.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	14.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	10.34 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	25.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	25.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	4.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	7.14 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	2.27 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	33.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	8.97 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	3.33 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	5.75 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	6.90 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	11.76 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	12.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	20.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	1.47 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	13.16 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	7.69 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	11.54 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	2.27 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	3.80 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	4.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	20.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	16.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	8.70 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	2.90 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	7.89 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	3.85 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	12.50 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	10.87 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	11.76 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	6.90 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	8.64 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	5.75 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	3.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	5.26 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	8.97 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	7.69 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Gastrointestinal Disorders (MedDRA Primary System Organ Class [SOC]), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	10.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were chills, face oedema, fatigue, injection site erythema, injection site pain, injection site swelling, and pyrexia.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 45	1.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 46	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	17.57 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 45	1.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	31.21 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	15.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 42	2.84 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 43	3.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 44	11.11 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	28.57 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 45	4.05 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 47	4.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 43	3.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 45	2.70 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 46	7.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 47	14.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 42	28.37 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 45	1.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 43	16.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	19.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 44	22.22 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 45	10.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 46	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 47	14.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 42	4.96 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 44	5.56 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 43	12.90 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 45	2.70 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 46	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 45	1.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 47	14.29 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	41.67 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 46	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 47	4.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 46	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 44	13.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	29.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 40	8.57 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 41	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 45	16.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 42	11.63 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 41	1.10 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 44	6.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	25.71 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 41	1.10 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 46	15.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 45	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 46	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 41	3.30 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 45	5.56 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 40	17.14 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 41	18.68 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 41	1.10 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 42	11.63 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 42	4.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 40	2.86 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 43	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 44	13.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	20.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 45	33.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 46	11.54 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	50.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	15.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 40	11.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 41	9.89 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	26.92 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 40	5.71 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 41	6.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 42	9.30 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 42	9.30 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	25.58 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 43	15.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 44	13.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 46	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 45	16.67 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 44	6.15 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	26.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	26.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	18.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	32.90 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	28.36 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	50.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	62.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 43	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 44	1.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 45	1.94 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 46	5.97 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 47	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 43	1.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 42	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 43	8.97 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 44	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 45	6.45 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 46	10.45 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 47	15.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 42	5.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 43	6.41 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 45	5.16 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 46	5.97 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 48	6.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 42	15.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 43	6.41 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 44	6.15 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 45	20.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 46	17.91 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 47	30.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 48	62.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 42	5.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 43	6.41 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 44	3.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 45	6.45 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 46	8.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 47	20.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 48	18.75 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 42	5.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 43	12.82 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 44	3.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 45	4.52 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 46	7.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 47	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 48	6.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 45	0.65 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 46	1.49 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 45	0.65 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 44	1.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 45	0.65 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 46	1.49 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 47	4.65 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	23.77 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 48	6.25 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 47	2.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 46	4.20 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 46	5.04 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 45	2.83 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 41	1.10 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 44	2.59 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 43	8.20 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 45	2.02 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 42	1.27 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	29.24 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pyrexia,Week 40	2.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 48	18.75 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 44	0.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 47	16.28 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 46	9.24 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 45	1.21 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 45	6.07 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 44	3.45 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 43	7.38 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 42	5.93 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 44	2.59 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pruritus,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 41	9.89 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site swelling,Week 40	11.43 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 48	62.50 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 47	20.93 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 43	2.46 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 46	13.45 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 45	18.22 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 44	12.07 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 43	9.02 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 42	1.69 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 42	22.46 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 41	18.68 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 41	3.30 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site pain,Week 40	17.14 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 48	6.25 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 46	0.84 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 47	6.98 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 46	6.72 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site warmth,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 45	4.05 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 44	5.17 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 41	1.10 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 43	4.92 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 42	3.81 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	62.50 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 41	7.69 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site erythema,Week 40	8.57 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	29.67 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 47	9.30 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 46	6.72 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 45	6.48 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	37.21 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 44	9.48 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 43	8.20 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	25.21 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 42	4.24 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 41	6.59 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	25.71 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 44	0.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Malaise,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Fatigue,Week 40	5.71 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	29.55 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 44	0.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	25.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 43	0.82 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling hot,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 44	0.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 46	1.68 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Face oedema,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Influenza like illness,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 41	1.10 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Feeling cold,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Peripheral swelling,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mucous membrane disorder,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Chills,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Injection site haematoma,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Discomfort,Week 42	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were chills, face oedema, fatigue, injection site erythema, injection site pain, injection site swelling, and pyrexia.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 47	36.84 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 48	4.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 49	2.94 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 50	4.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 51	8.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 52	25.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Chills,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Chills,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Chills,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Chills,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Chills,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Chills,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Chills,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Face oedema,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Face oedema,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Face oedema,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Face oedema,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Face oedema,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Face oedema,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Face oedema,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Fatigue,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Fatigue,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Fatigue,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Fatigue,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Fatigue,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Fatigue,Week 51	8.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Fatigue,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site erythema,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site erythema,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site erythema,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site erythema,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site erythema,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site erythema,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site erythema,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site pain,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site pain,Week 47	31.58 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site pain,Week 48	4.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site pain,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site pain,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site pain,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site pain,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site swelling,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site swelling,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site swelling,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site swelling,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site swelling,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site swelling,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Injection site swelling,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Pyrexia,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Pyrexia,Week 47	10.53 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Pyrexia,Week 48	4.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Pyrexia,Week 49	2.94 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Pyrexia,Week 50	4.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Pyrexia,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Pyrexia,Week 52	25.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°40 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	17.65 percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	100 percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	18.31 percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	21.05 percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	42.86 percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	33.06 percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	21.43 percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	15.38 percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	42.86 percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	17.24 percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	9.09 percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	42.31 percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	50.00 percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	36.59 percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	10.00 percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	62.50 percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	24.00 percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	35.71 percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	40.00 percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	15.91 percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	33.33 percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	16.67 percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	66.67 percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	26.92 percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	16.67 percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	24.14 percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	24.14 percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	47.06 percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	62.50 percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	40.00 percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	44.12 percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	31.58 percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	26.92 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	66.67 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	32.69 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	15.91 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	44.30 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	24.00 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	40.00 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	16.67 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	17.39 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	34.06 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	36.59 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	18.42 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	42.31 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	62.50 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	34.78 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	47.06 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	24.14 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	20.99 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	24.14 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	16.67 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	15.79 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	26.92 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	26.92 percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	20.00 percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were anaphylactic reaction and hypersensitivity.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	1.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 45	1.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hypersensitivity,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Anaphylactic reaction,Week 43	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	0 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. Age strata were defined as 6 months to 17 years, 18 to 65 years and \>65 years. All subjects who received the second dose of vaccine, were in the first age stratum: 6 months to 17 years. Please, refer to outcome n°42 for the overall (across age strata) post-dose 2 results.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	1.41 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	6 months to 17 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	18-65 years,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 45	1.23 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1, by Vaccine Group and Overall, and by Age Category	>65 years,Week 41	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were conjunctivitis and rhinitis.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 46	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 43	3.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	8.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 47	4.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 44	5.56 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	4.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 43	3.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	9.46 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 44	5.56 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 45	2.70 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	6.45 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 45	8.11 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 42	0.71 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 40	4.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 41	3.30 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 42	2.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 42	4.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 43	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	8.79 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 46	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	6.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 40	4.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 41	6.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 42	2.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 44	6.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 45	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	8.57 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 40	1.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	4.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 46	4.48 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	5.13 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	6.15 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	5.81 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	8.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	15.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	12.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 43	1.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 44	1.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 45	3.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 46	5.97 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 47	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 48	6.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 43	2.56 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 44	3.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 45	2.58 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 47	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 44	1.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 44	1.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 47	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 45	0.65 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 48	6.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 43	1.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 41	3.30 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	8.79 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 44	0.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 43	0.82 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 40	4.29 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Ear infection,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	12.50 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 44	0.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	9.30 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	7.56 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasopharyngitis,Week 48	6.25 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 40	1.43 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Bronchitis,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	8.57 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 47	2.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 46	2.52 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 45	3.24 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 44	4.31 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	7.29 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 43	2.46 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 42	1.27 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	6.90 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 41	6.59 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinitis,Week 40	4.29 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 48	6.25 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 47	4.65 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	5.74 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oral herpes,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 46	5.88 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 45	4.45 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 47	2.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hordeolum,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 44	2.59 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 43	2.46 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	1.69 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Upper respiratory tract infection,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 42	0.42 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Herpes simplex,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Conjunctivitis,Week 42	1.27 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Laryngitis,Week 46	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were conjunctivitis and rhinitis.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 48	12.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 50	2.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Conjunctivitis,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Conjunctivitis,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Conjunctivitis,Week 48	8.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Conjunctivitis,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Conjunctivitis,Week 50	2.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Conjunctivitis,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Conjunctivitis,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinitis,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinitis,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinitis,Week 48	4.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinitis,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinitis,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinitis,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinitis,Week 52	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for injury, poisoning and procedural complications.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 45	5.56 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	5.56 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Muscle strain,Week 47	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. There were no predefined AEIs listed on the ADR card for injury, poisoning and procedural complications.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	0 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for investigations.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	1.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 45	1.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	4.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 42	4.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 43	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.85 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.82 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 42	0.85 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 43	0.82 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Heart rate increased,Week 47	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. There were no predefined AEIs listed on the ADR card for investigations.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	0 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card was decreased appetite.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	4.05 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 47	4.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 46	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 45	4.05 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	4.76 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	1.10 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 41	1.10 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	12.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 45	3.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 42	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 43	11.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 44	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	11.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	3.87 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 48	12.50 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 42	1.27 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	5.17 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	1.27 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 43	7.38 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 48	12.50 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 46	0.84 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 44	5.17 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	2.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	7.38 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	12.50 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.84 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 45	3.64 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 41	1.10 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	1.10 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Decreased appetite,Week 47	2.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	3.64 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card was decreased appetite.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Decreased appetite,Week 48	4.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 47	5.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 48	4.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 50	2.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Decreased appetite,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Decreased appetite,Week 47	5.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Decreased appetite,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Decreased appetite,Week 50	2.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Decreased appetite,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Decreased appetite,Week 52	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were arthropathy and myalgia.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 47	4.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	11.54 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 42	9.93 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	4.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 44	8.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 45	9.46 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	11.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 46	11.54 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	19.44 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 42	1.42 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	10.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 44	13.89 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 45	2.70 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 46	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 44	6.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	23.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 45	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 46	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 45	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 40	1.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	6.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 41	2.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 41	1.10 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 42	2.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	5.71 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 45	5.56 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	2.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 43	15.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 45	5.56 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 42	2.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 42	2.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	15.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 40	5.71 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 41	5.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 46	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 46	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 43	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	16.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 44	1.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 43	6.41 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 46	1.49 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 44	1.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 45	6.45 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 46	7.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	37.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 44	1.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 47	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 48	31.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 43	1.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 42	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 45	3.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	8.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	3.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 47	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	8.39 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 48	18.75 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 41	1.10 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	5.71 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	7.69 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	8.90 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	7.38 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	8.62 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	9.72 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	10.92 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	4.65 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	37.50 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 40	1.43 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 41	2.20 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 42	1.27 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 43	1.64 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 44	5.17 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 45	3.64 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 46	3.36 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 47	4.65 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Arthropathy,Week 48	18.75 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 40	5.71 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 41	5.49 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 42	7.63 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 43	4.92 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 44	4.31 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 45	7.69 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 46	8.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 47	2.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Myalgia,Week 48	31.25 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Limb discomfort,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 42	0.42 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Musculoskeletal pain,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 43	0.82 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pain in extremity,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 42	0.42 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 46	0.84 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rheumatic disorder,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 44	0.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Synovial cyst,Week 48	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were arthropathy and myalgia.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 47	5.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Arthropathy,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Arthropathy,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Arthropathy,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Arthropathy,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Arthropathy,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Arthropathy,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Arthropathy,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Myalgia,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Myalgia,Week 47	5.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Myalgia,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Myalgia,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Myalgia,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Myalgia,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Myalgia,Week 52	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were febrile convulsion and headache.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	13.51 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 45	10.81 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 44	16.67 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 42	4.96 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 43	9.68 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 45	1.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	9.68 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 45	2.70 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	16.67 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	5.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 40	4.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	4.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	6.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	15.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	50.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	5.71 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 41	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 42	4.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 43	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 44	6.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 45	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 46	15.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 47	50.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 40	1.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 45	0.65 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	37.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	8.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 43	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	9.68 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 44	1.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 45	7.74 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 45	0.65 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 46	8.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 47	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 48	37.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	1.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 45	0.65 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 45	8.91 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	4.65 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	4.66 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 46	8.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	8.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 47	4.65 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 48	37.50 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 42	0.42 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	10.93 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	6.90 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 42	4.24 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 45	1.21 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	8.20 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	7.69 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Somnolence,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	5.71 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Aphonia,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 43	8.20 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dizziness,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 41	7.69 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 40	1.43 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 44	6.90 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	37.50 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Headache,Week 40	4.29 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Poor quality sleep,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Febrile convulsion,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Tremor,Week 43	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were febrile convulsion and headache.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	0 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEI listed on the ADR card was irritability.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 45	1.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 46	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	1.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 42	2.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 42	6.98 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 43	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 42	2.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	9.30 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 44	1.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 43	5.13 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 44	3.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	3.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 45	0.65 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 46	2.99 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 47	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.65 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	2.99 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	5.13 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	2.12 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	4.10 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	2.59 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.81 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	2.52 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	2.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 42	1.69 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 43	4.10 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 44	2.59 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 45	0.81 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 46	2.52 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 47	2.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Irritability,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 42	0.42 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Insomnia,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 44	0.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Mood swings,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 42	0.42 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sleep disorder,Week 47	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEI listed on the ADR card was irritability.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 48	8.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 49	5.88 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Irritability,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Irritability,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Irritability,Week 48	8.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Irritability,Week 49	5.88 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Irritability,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Irritability,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Irritability,Week 52	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were cough, dysphonia, epistaxis, nasal congestion, oropharyngeal pain, rhinorrhoea, and wheezing.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 47	4.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 45	2.70 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	9.52 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 42	1.42 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 46	3.85 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 42	2.84 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 43	6.45 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 42	3.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 45	5.41 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 43	3.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 47	4.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 46	7.69 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 45	16.22 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 44	16.67 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 43	16.13 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 43	3.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 42	3.55 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 45	2.70 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 42	2.84 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 43	3.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	9.93 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 43	3.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	19.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 44	8.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	25.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 44	2.78 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	20.27 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 40	5.71 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 41	5.49 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 42	6.98 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	8.57 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	13.19 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	9.30 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	23.08 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	6.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	22.22 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 41	2.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 45	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 40	7.14 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 41	2.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 42	4.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 46	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 45	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 40	4.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 42	2.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 40	4.29 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 41	6.59 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 42	6.98 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 43	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 45	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 46	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 42	2.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 43	15.38 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 42	6.98 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 45	11.11 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 40	5.71 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 41	2.20 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 42	4.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 42	4.65 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 43	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 43	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 44	6.67 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 41	1.10 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 44	3.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 45	5.16 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	18.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 47	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	25.64 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 45	2.58 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	26.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 44	9.23 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 43	2.56 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 42	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 43	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 44	1.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 48	12.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 47	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 43	1.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 43	1.28 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 42	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 42	15.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 43	10.26 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 48	18.75 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 44	10.77 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 48	12.50 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 46	8.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 45	10.32 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 47	5.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 47	10.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 46	8.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 46	8.96 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 47	15.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 48	18.75 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 44	1.54 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 45	6.45 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 44	12.31 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 45	2.58 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 46	7.46 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 43	15.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 44	3.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 42	15.38 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 45	5.16 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 43	7.69 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	31.25 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	30.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	20.90 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	21.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 46	1.49 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 48	12.50 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 40	4.29 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 41	1.10 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 42	2.97 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 43	2.46 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 44	0.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 45	2.43 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 46	0.84 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 47	2.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dysphonia,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 41	2.20 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 42	0.42 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 43	1.64 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 45	1.62 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Epistaxis,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 40	5.71 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 41	2.20 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 42	5.93 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 43	6.56 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 44	8.62 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 45	4.05 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 46	5.04 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 47	2.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Nasal congestion,Week 48	12.50 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 40	5.71 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 41	5.49 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 42	3.81 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 43	5.74 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 44	2.59 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 45	4.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 46	5.88 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 47	2.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Oropharyngeal pain,Week 48	18.75 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 40	4.29 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 41	6.59 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 42	5.08 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 43	10.66 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 44	11.21 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 45	12.15 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 46	7.56 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 47	6.98 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rhinorrhoea,Week 48	18.75 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 42	0.85 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 43	1.64 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 44	1.72 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Wheezing,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 44	0.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dry throat,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 42	0.85 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 43	0.82 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Dyspnoea,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 43	0.82 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Increased upper airway secretion,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 43	0.82 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 44	1.72 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Sneezing,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 47	2.33 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Throat clearing,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	8.57 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	13.19 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	13.56 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	23.77 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	18.97 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	21.05 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	15.13 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	18.60 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	31.25 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 40	7.14 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 41	2.20 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 42	5.93 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 43	11.48 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 44	7.76 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 45	6.48 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 46	5.04 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Cough,Week 47	6.98 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were cough, dysphonia, epistaxis, nasal congestion, oropharyngeal pain, rhinorrhoea, and wheezing.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Cough,Week 50	4.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Cough,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Cough,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Dysphonia,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Dysphonia,Week 47	5.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Dysphonia,Week 48	8.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Dysphonia,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Dysphonia,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Dysphonia,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Dysphonia,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Epistaxis,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Epistaxis,Week 47	5.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Epistaxis,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Epistaxis,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Epistaxis,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Epistaxis,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Epistaxis,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nasal congestion,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nasal congestion,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nasal congestion,Week 48	12.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nasal congestion,Week 49	2.94 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nasal congestion,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nasal congestion,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Nasal congestion,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Oropharyngeal pain,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Oropharyngeal pain,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Oropharyngeal pain,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Oropharyngeal pain,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Oropharyngeal pain,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Oropharyngeal pain,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Oropharyngeal pain,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinorrhoea,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinorrhoea,Week 47	5.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinorrhoea,Week 48	20.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinorrhoea,Week 49	5.88 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinorrhoea,Week 50	2.38 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinorrhoea,Week 51	8.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rhinorrhoea,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Wheezing,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Wheezing,Week 47	5.26 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Wheezing,Week 48	4.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Wheezing,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Wheezing,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Wheezing,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Wheezing,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Sneezing,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Sneezing,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Sneezing,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Sneezing,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Sneezing,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Sneezing,Week 51	8.33 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Sneezing,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 47	15.79 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 48	36.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 49	8.82 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 50	4.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 51	16.67 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Cough,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Cough,Week 47	15.79 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Cough,Week 48	20.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Cough,Week 49	8.82 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. The pre-defined AEIs listed on the ADR card were rash and rash generalised.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 45	1.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 45	1.35 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 45	2.70 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	6.76 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 43	3.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 42	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 45	2.70 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	3.23 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 40	1.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 41	1.10 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 42	2.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 43	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	7.69 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 46	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	2.33 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	1.10 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	2.86 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 46	3.85 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 40	1.43 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 40	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 45	0.65 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	3.85 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	3.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	1.29 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 42	1.92 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 44	3.08 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 45	0.65 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 46	0.84 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 45	0.81 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 46	0.84 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	1.64 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 43	1.64 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	1.72 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 42	0.42 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 41	1.10 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	2.83 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 40	1.43 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.84 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 40	1.43 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 42	0.42 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hyperhidrosis,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 44	1.72 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 45	0.40 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 45	0.81 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 45	0.81 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 42	0.42 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Rash generalised,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 42	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	2.86 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus generalised,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	1.10 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Pruritus,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Erythema,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	1.27 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. The pre-defined AEIs listed on the ADR card were rash and rash generalised.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 48	4.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Any,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash,Week 48	4.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash,Week 52	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash generalised,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash generalised,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash generalised,Week 48	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash generalised,Week 49	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash generalised,Week 50	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash generalised,Week 51	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	Rash generalised,Week 52	0.00 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a first dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 40 and 52. No vaccination (Dose 1) was administered from ISO week 49 onwards. There were no predefined AEIs listed on the ADR card for vascular disorders.

Time frame: Within 7 days post Dose 1 i.e. the day of vaccination and the following 6 days

Population: Analysis was performed on the enrolled subjects who were vaccinated with the first dose of GSK's quadrivalent seasonal influenza vaccine and who returned the ADR card.

Arm	Measure	Group	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 44	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.71 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 46	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 43	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 40	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 41	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 42	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 43	0.00 Percentage of subjects
Vaccinated_Influsplit Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 48	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 44	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 47	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 43	0.00 Percentage of subjects
Vaccinated_Fluarix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 48	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 40	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 41	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 42	0.42 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 43	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 44	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 45	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 46	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Hot flush,Week 47	0.00 Percentage of subjects
Total Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall	Any,Week 42	0.42 Percentage of subjects

Secondary

Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

The weekly percentage of subjects was calculated as follows (per 100 subjects): the denominator was the number of subjects vaccinated with a second dose of the GSK's quadrivalent seasonal influenza vaccine at the week of interest; the numerator was the number of subjects among those vaccinated subjects, who reported the AE at least once on the ADR card within 7 days following vaccination at the same week. Vaccination period was defined between ISO weeks 46 and 52. There were no predefined AEIs listed on the ADR card for vascular disorders.

Time frame: Within 7 days post Dose 2 i.e. the day of vaccination and the following 6 days

Arm	Measure	Value (NUMBER)
Vaccinated_AlphaRix Tetra Group	Weekly Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group	0 Percentage of subjects

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026

Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs) Using Adverse Drug Reaction (ADR) Card, Post Dose 1 by Vaccine Group and Overall

Cumulative Percentage of Subjects Reporting Any AEIs and/or AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

Cumulative Percentage of Subjects Reporting Cardiac Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

Cumulative Percentage of Subjects Reporting Ear and Labyrinth Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

Cumulative Percentage of Subjects Reporting Eye Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA Preferred Term [PT], Using ADR Card, Post Dose 1 by Vaccine Group and Overall

Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

Cumulative Percentage of Subjects Reporting General Disorders and Administration Site Conditions by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall

Cumulative Percentage of Subjects Reporting Immune System Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall

Cumulative Percentage of Subjects Reporting Infections and Infestations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

Cumulative Percentage of Subjects Reporting Injury, Poisoning and Procedural Complications by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

Cumulative Percentage of Subjects Reporting Investigations by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 1, by Vaccine Group and Overall

Cumulative Percentage of Subjects Reporting Metabolism and Nutrition Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

Cumulative Percentage of Subjects Reporting Musculoskeletal and Connective Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

Cumulative Percentage of Subjects Reporting Nervous System Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

Cumulative Percentage of Subjects Reporting Psychiatric Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

Cumulative Percentage of Subjects Reporting Respiratory, Thoracic and Mediastinal Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

Cumulative Percentage of Subjects Reporting Skin and Subcutaneous Tissue Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 1 by Vaccine Group and Overall

Cumulative Percentage of Subjects Reporting Vascular Disorders by MedDRA PT, Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group

Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

Cumulative Percentage of Subjects Reporting Any AEs Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Cumulative Percentage of Subjects Reporting Any Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

Cumulative Percentage of Subjects Reporting Any Cardiac Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

Cumulative Percentage of Subjects Reporting Any Ear and Labyrinth Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

Cumulative Percentage of Subjects Reporting Any Eye Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

Cumulative Percentage of Subjects Reporting Any Gastrointestinal Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

Cumulative Percentage of Subjects Reporting Any General Disorders and Administration Site Conditions (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category

Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Risk Status

Cumulative Percentage of Subjects Reporting Any Immune System Disorders (MedDRA Primary SOC), Using ADR Card, Post Dose 2 in the Vaccinated_Fluarix Tetra Group, by Risk Status

Cumulative Percentage of Subjects Reporting Any Infections and Infestations (MedDRA Primary SOC), Using ADR Card, Post Dose 1 by Vaccine Group and Overall, by Age Category